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ABSTRACT 
Adolescence is a vulnerable developmental period in regards to drug 
initiation and use. The gateway hypothesis suggests that adolescent cigarette 
smoking may result in a heightened risk for methamphetamine use. However, 
little is understood about the role of nicotine on adolescent methamphetamine 
addiction. The aim of the present study was to determine whether early, late, or 
continuous adolescent nicotine exposure would alter oral methamphetamine self-
administration, extinction, or reinstatement. A total of 164 male and female 
Sprague-Dawley rats were pretreated with saline or nicotine (0.16, or 0.64 mg/kg, 
sc) beginning on postnatal day (PD) 25 for 10 consecutive days. On PD 35, rats 
in the 0.16 and 0.64 mg/kg pretreatment groups were evenly divided and 
assigned to a group that either continued to receive the same nicotine dose they 
received as adolescents or saline. Rats that had received saline as adolescents 
were divided into three equal groups, where they received 0.16 or 0.64 mg/kg 
nicotine or continued to receive saline injections. Drug treatments starting on PD 
35 continued until the end of the experiment. Thus, there were a total of 7 
groups: SAL–SAL, 0.16–0.16, 0.16–SAL, SAL-0.16, 0.64–0.64, 0.64–SAL, SAL-
0.64. On PD 35, all rats began nose poke training. Rats were exposed to a 
methamphetamine fade in, sucrose fade out procedure across 5 different 
methamphetamine-sucrose combinations. This procedure resulted in exposure to 
a 40 mg/l methamphetamine solution for 3 consecutive days on a FR2 schedule. 
Following the last day of methamphetamine self-administration, rats were 
iv 
exposed to extinction training. Once the extinction criteria were met, rats were 
given a priming injection of methamphetamine (1.0 mg/kg, ip). Data from the 
present investigation revealed two main important findings: a) acquisition of oral 
methamphetamine self-administration can be attained in adolescent rats; and b) 
adolescent nicotine exposure differentially alters oral methamphetamine self-
administration. Exposure to a low dose of nicotine (0.16 mg/kg), but not a high 
dose of nicotine (0.64 mg/kg), attenuated consumption and responding for 
methamphetamine during self-administration. During the extinction and 
reinstatement periods, we found that nicotine (0.16 or 0.64 mg/kg) exposure did 
not alter consumption or responding for methamphetamine. Female rats showed 
augmented total active nose pokes and active nose pokes within the 
reinforcement period compared to male rats. Conversely, male rats showed 
augmented sucrose and methamphetamine solution consumption across 
methamphetamine acquisition sessions 1–6. These data suggest that for 
adolescents who already present moderate cigarette smoking behavior at the 
time of methamphetamine cessation treatment, total abstinence from both 
nicotine and methamphetamine may be a less effective form of treatment. It may 
be clinically beneficial to first treat the methamphetamine addiction, and 
subsequently treat the nicotine addiction. Regardless of the method of treatment 
for adolescent methamphetamine addiction, nicotine exposure should be closely 
monitored. 
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CHAPTER ONE 
DRUG ADDICTION 
Introduction 
Drug addiction is a progressive, complex, and multidimensional disease 
(Baler & Volkow, 2006; Everitt & Robbins, 2005; Koob & Le Moal, 1997). The 
National Institute of Drug Addiction (NIDA) defines drug addiction as a “chronic, 
relapsing brain disease, which is characterized by compulsive drug seeking and 
use, despite harmful consequences” (NIDA, National Institute of Health [NIH], & 
US Department of Health and Human Services [UDHHS], 2010). Initial voluntary 
stages of drug use are typically characterized by reward and feelings of euphoria 
(Everitt, 2014; Wise & Koob, 2014). However, prolonged drug use leads to a loss 
of control over drug taking and can eventually result in addiction (Everitt, 2014; 
Wise & Koob, 2014). A variety of potential factors influence the transition from 
recreational drug use to drug addiction, including route of administration, 
genetics, history of drug use, stress, and life events (Koob & Le Moal, 1997). 
Drug addiction ultimately leaves addicted individuals with detrimental 
physiological, psychological, behavioral, and sociocultural changes (Everitt, 
2014; Everitt & Robbins, 2005; Volkow & Morales, 2015).  
The stages of drug addiction are depicted in some theories as a complex, 
downward spiraling model (Everitt, 2014; Koob, 2000; Koob & Le Moal, 1997). 
These theories suggest that individuals who possess characteristic behavioral 
traits (e.g., impulsivity, novelty-seeking, or anxiety) may be more vulnerable to 
2 
drug initiation (Everitt, 2014; Koob & Le Moal, 1997). These behavioral traits may 
lead to acquisition of drug self-administration, wherein drug-cued learning and 
drug-induced cognitive impairments occur (Everitt, 2014; Koob & Le Moal, 1997). 
Consequently, continued drug use and habitual drug-taking patterns take form 
via conditioned reinforcement (Everitt, 2014; Koob & Le Moal, 1997). Initially, 
addictive drugs act as positive reinforcers, in which positive associations from the 
drug-taking experience increase the probability of later drug-seeking behavior 
(Gilpin & Koob, 2008; Wise & Koob, 2014). Continued drug use results in a 
transition where the user becomes physiologically dependent on the drug (Wise 
& Koob, 2014). With drug tolerance (i.e., increased reward thresholds) in place, 
addictive drugs become negatively reinforcing when the probability of drug 
seeking increases in order to alleviate aversive withdrawal symptoms (Gilpin & 
Koob, 2008). Following binges and heavy intoxication, compulsive drug use (i.e., 
addiction) takes hold, resulting in failures in executive control (Everitt, 2014; 
Koob & Le Moal, 1997). After repeated drug withdrawals, the user is likely to 
experience relapse (Baler & Volkow, 2006). 
Relapse is one of the major problems associated with the treatment of 
drug addiction (Koob, 2013; Marchant, Li, & Shaham, 2013; Robinson & 
Berridge, 2008). Drug addiction relapse rates (e.g. 40-60%) are substantial and 
compare to relapse rates of other major chronic illnesses (McLellan, Lewis, 
O'Brien, & Kleber, 2000). Prolonged drug use results in repeated drug-associated 
pairings, such as with social, physical, or emotional contexts (McLellan et al., 
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2000). Following periods of abstinence, a drug user may encounter many of 
these previously drug-paired contexts, which can generate profound 
psychological reactions (McLellan et al., 2000). Thus, relapse is often driven by 
the subjective desires or cravings for a drug triggered by previous drug-paired 
contexts (O'Brien, 2005). In addition, relapse may result from acute re-exposure 
to the drug or stress (Koob & Le Moal, 1997). 
Adolescent drug use is of major concern because of the increased level of 
detrimental effects associated with early drug exposure (Odgers et al., 2008). For 
example, exposure to illicit drugs during adolescence is linked to sexually 
transmitted diseases, teen pregnancy, low educational attainment, and crime 
(Odgers et al., 2008). Further, illicit drug and alcohol exposure prior to the age of 
15 is a robust indicator of substance use disorders in adulthood (Grant & 
Dawson, 1997). 
Cigarette smoking during adolescence is particularly problematic because 
it leads to a number of adverse consequences. Of specific interest, is the 
relationship between early onset of cigarette smoking and later use of illicit drugs 
(Lewinsohn, Rohde, & Brown, 1999). For example, early onset of nicotine use 
has been associated with early stimulant and marijuana use (Rubinstein, Rait, & 
Prochaska, 2014; Weinberger & Sofuoglu, 2009). Indeed, approximately 97% of 
methamphetamine users are regular users of tobacco (Brecht et al., 2004; 
Brecht, Greenwell, & Anglin, 2007). Moreover, preclinical studies show that early 
exposure to nicotine can increase the reinforcing effects and reduce the aversive 
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effects of drugs (e.g., Neugebauer, Harrod, & Bardo, 2010; Pipkin et al., 2014). 
Importantly, psychostimulant users who also smoke tobacco experience 
increased stimulant dependence and health problems, as well as poorer 
treatment outcomes (Weinberger & Sofuoglu, 2009).  
In the current proposal, we aim to investigate the effects of nicotine 
exposure on the reinforcing properties of methamphetamine in adolescent rats. 
To this end, we will assess adolescent nicotine exposure on acquisition of 
methamphetamine oral self-administration, extinction, and reinstatement. The 
following chapters discuss the importance of the adolescent period, relevant 
neurotransmitter systems, nicotine, methamphetamine, self-administration 
paradigm, and the rationale for the proposed study. 
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CHAPTER TWO 
ADOLESCENCE 
Introduction 
Adolescence is a pivotal transitional period during development that 
bridges the gap between childhood and adulthood. The adolescent period is 
typically regarded as roughly 10 to 19 years of age and characterized by many 
different hormonal, physical, psychological, and social changes (Sacks, 2003). 
Specifically, early adolescence (i.e., ~10-14 years) is characterized by the onset 
of physical (e.g., onset of puberty), cognitive (e.g., abstract thought), social (e.g., 
sense of identity), and emotional (e.g., mood swings) development (Blakemore, 
2012; Dumontheil, 2014; Marcia, 1980; Sawyer et al., 2012; Zeman, Cassano, 
Perry-Parrish, & Stegall, 2006). In late adolescence (i.e., ~15-19 years), physical 
changes begin to subside, while the ability for abstract thought, cognitive control, 
drive for independence, and emotional regulation continues to develop 
(Blakemore, 2012; Dumontheil, 2014; Marcia, 1980; Sawyer et al., 2012; Zeman 
et al., 2006).   
The complex changes experienced during adolescence promote 
increased risk-taking behavior (e.g., substance use, unsafe sex, illegal activities, 
and dangerous driving) (Bond, Carlin, Thomas, & Patton, 2001; Herrenkohl et al., 
2000). Social development in adolescents is characterized by a need for 
independence, in which less time is spent with parents or family and more time is 
spent with peer groups (Gorrese & Ruggieri, 2012). Increases in peer-influence 
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may potentially lead to risky behavior, such as substance use (Berndt, 1979; 
Spear, 2000). Risk-taking behavior may also result from the positive association 
with the novelty, complexity, or intensity of a new experience, which often is the 
reason for adolescent drug initiation (Arnett, 1992). 
Throughout adolescence there are many changes in the development of 
brain areas that responsible for response inhibition, risk, reward, and emotion 
(Steinberg, 2005). Specifically, subcortical areas (e.g., ventral striatum, nucleus 
accumbens, hippocampus, and amygdala) involved in emotion, motivation, and 
reward, develop in early adolescence (Crews, He, & Hodge, 2007; Wetherill & 
Tapert, 2012). Cortical brain areas such as the prefrontal cortex, which is 
important in executive functioning (e.g., inhibitory control), do not finalize 
connections until early adulthood, suggesting that adolescents may lack impulse 
control and effective decision-making processes, while maintaining increases in 
motivation, emotion, and reward sensitivity (Casey & Jones, 2010; Luciana, 
2013; Steinberg, 2010; Wetherill & Tapert, 2012). Given the weak top-down 
cognitive control and heightened emotional reactivity evident during normal 
adolescent brain development, adolescents are susceptible to difficulties with 
affect, risk-taking, inhibitory control, and reward-related behaviors, all of which 
play a role in substance initiation and use (Casey & Jones, 2010). 
Depending on the brain area and period of development, many neurons in 
the brain undergo synaptic pruning, in which the number of neural connections 
are reduced (Giedd et al., 1999; Gogtay et al., 2004). This synaptic pruning leads 
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to decreased cortical volume and thickness (Giedd et al., 1999; Gogtay et al., 
2004). For example, during adolescence, pruning takes place in the amygdala, 
nucleus accumbens, and prefrontal cortex (Andersen, Thompson, Rutstein, 
Hostetter, & Teicher, 2000; Teicher, Andersen, & Hostetter, 1995; Zehr, Todd, 
Schulz, McCarthy, & Sisk, 2006). Although this pruning process is not entirely 
understood, the neuronal remodeling that occurs during adolescence maybe an 
essential stage to facilitate developmental plasticity that helps prepare for more 
mature behavior in adulthood (Crews et al., 2007). However, this period of 
neuronal change results in adolescents being more vulnerable to alterations in 
the neuronal environment brought about by psychopharmacological agents 
(Geier, 2013). 
Adolescence and Drug Addiction 
Adolescence is a period of increased illicit drug initiation because 
adolescents often display impulsivity in decision-making (Kalivas & Volkow, 
2005). Many adult smokers begin smoking within their teenage years, which 
often leads to health complications (UDHHS, 2012). Based on a self-report 
measure of adults with substance use disorders, the median age for illicit drug 
initiation was 16, and initiation after age 20 was rare (Good & Radcliffe, 2011).  
Cessation of smoking is more difficult for individuals who begin smoking at an 
earlier age when compared to those who initiate smoking later in life (Stanton & 
Grimshaw, 2013). Additionally, nicotine addiction in adolescence develops 
rapidly, creating difficulty for smoking cessation in this age group (DiFranza & 
8 
Richmond, 2008). The use of nicotine in adolescence produces a more sensitive 
response to the positive rewarding and reinforcing effects of nicotine (Torres, 
Tejeda, Natividad, & O’Dell, 2008; Kota, Martin, Robinson, & Damaj, 2007).  
Similar to nicotine, methamphetamine is a highly addictive psychoactive 
drug that poses enormous problems for society (Panenka et al., 2013). Due to 
the relatively easy synthesis and production, as well as the highly addictive 
nature of methamphetamine, the drug has become one of the most widely used 
and distributed psychostimulants in the world (United Nations Office on Drugs 
and Crime [UNODC], 2010). In a 2010 Monitoring the Future study, it was found 
that adolescent methamphetamine use among high school students was 1.6% 
(Panenka et al., 2013). Although methamphetamine use in adolescence declined 
in 2010, the prevalence rates for methamphetamine use have fluctuated 
substantially throughout past decades (Johnston, O’Malley, Bachman, & 
Schulenberg, 2012). Evidence from animal models suggest that adolescents may 
be more vulnerable to the effects of methamphetamine and other drugs of abuse, 
because they are less sensitive to withdrawal and can develop robust drug 
sensitization when drug use initiates in early to mid-adolescence (Schramm-
Sapyta, Walker, Caster, Levin, Kuhn, 2009).    
Given the many neurological changes during adolescence, the effects of 
psychostimulants like nicotine and methamphetamine on the vulnerable 
adolescent brain need to be considered in more detail. In order to study the 
effects of these addictive psychostimulants on the adolescent brain and resulting 
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behavior, it is imperative to understand changes in relevant neurotransmitter 
systems across the period of adolescence. Therefore, the following two chapters 
will give an overview of the cholinergic and monoamine neurotransmitter 
systems. 
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CHAPTER THREE 
ACETYLCHOLINE 
Introduction 
Acetylcholine (ACh) was the first neurotransmitter to be identified and is 
found in both the central and peripheral nervous systems (Sofuoglu & Mooney, 
2009; Stjärne, 1999). Peripheral action of ACh at the neuromuscular junction is 
vital for skeletal and cardiac muscle contraction (Brown, Wetzel, & Dunlap, 1982; 
Fambrough, 1979). Within the central nervous system (CNS), ACh is involved in 
numerous psychological processes, including addiction, attention, arousal, 
motivation, mood, reward, learning, memory, and stress (Acquas, Wilson, & 
Fibiger, 1996; Mansvelder & McGehee, 2002; Pepeu & Blandina, 1998; 
Poorthuis & Mansvelder, 2013; Robbins, 1997; Thiel, Huston, & Schwarting, 
1998; Warner-Schmidt et al., 2012). Neurological and psychiatric disorders that 
are due to cholinergic dysfunction include, Parkinson’s, Alzheimer’s, bipolar 
disorder, schizophrenia, and substance use disorders (Lester, Rogers, & Blaha, 
2010; Levin, 2012; Maskos, 2008; McEvoy & Allen, 2002). 
Acetylcholine Synthesis, Release, and Catabolism 
The synthesis of ACh is initiated in the presynaptic terminals of cholinergic 
neurons. Within these cholinergic neurons, ACh is formed from the two 
compounds choline and acetyl-CoA in the presence of the enzyme choline 
acetyltransferase (ChaT) (Parsons, Prior, & Marshall, 1993; Prado et al., 2002; 
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Scremin & Jenden 1993). In addition to producing ACh, ChaT levels are often 
used as a marker to determine if a neuron is cholinergic (Kimura, McGeer, Peng, 
& McGeer, 1980). Intracellular choline concentrations are determined by the 
uptake of choline into the presynaptic axon terminal by the high-affinity choline 
transporter (CHT1) (Bellier & Kimura, 2011; Simon, Atweh, & Kuhar, 1976). In 
the process of ACh synthesis, choline serves as the rate-limiting step (Bellier & 
Kimura, 2011; Simon et al., 1976). After formation, ACh is then accumulated in 
synaptic vesicles by the actions of the vesicular acetylcholine transporter 
(VAChT) (Parsons et al., 1993; Prado et al., 2002; Scremin & Jenden, 1993). 
In response to an action potential reaching the axon terminal, an influx of 
extracellular calcium (Ca2+) enters the neuron through voltage-gated Ca2+ 
channels. ACh containing vesicles then bind to the cytosolic neuronal membrane, 
allowing for the subsequent release of ACh into the synaptic cleft (Dunant & 
Israel, 2000; Langley & Grant, 1997; Lima, Prado, Prado, & Kushmerick, 2010). 
The action of ACh containing vesicles fusing to the neuronal membrane is 
promoted by the binding of vesicle soluble N-ethylmaleimide-sensitive-factor 
attachment-protein receptor, or v-SNARE to a corresponding target SNARE (t-
SNARE) on the active zone of the cytoplasmic membrane (Dunant & Israel, 
2000; Israel & Dunant, 1998). 
The release of ACh by the presynaptic neuron into the synaptic cleft 
results in diffusion of ACh to the post-synaptic neuron, where ACh either binds to 
cholinergic receptors and/or is subjected to enzymatic degradation by 
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acetylcholinesterase (AChE) into choline and acetic acid (Prado, Roy, Kolisnyk, 
Gros, & Prado, 2013; Silman & Sussman, 2005). The choline is then recycled 
back into the terminal of the presynaptic neuron by uptake, predominately carried 
out by CHT1 (Matsuo et al., 2011). 
Acetylcholine Receptors and Subtypes 
  ACh receptors are divided into two major classes: muscarinic (mAChRs) 
and nicotinic (nAChRs) receptors (Picciotto, Higley, & Mineur, 2012). The 
receptors were named based on the drugs that bound to them. Specifically, the 
stimulant nicotine binds to nAChRs, whereas the psychoactive ingredient in 
certain mushrooms, muscarine, binds to mAChRs (Haga, 2013; Papke, 2014). 
The mAChRs are metabotropic receptors, which promote the initiation of second 
messenger systems and indirectly open ion channels on the post-synaptic 
neuron (Wess, 2003). The five subtypes of mAChRs (i.e., M1-5) are all classified 
as G-protein-coupled receptors, of which the M1, M3, and M5 type belong to the 
Gq family, whereas M2 and M4 belong to the Gi/o family (Caulfield & Birdsall, 
1998; Haga, 2013; Picciotto et al., 2012; Wess, 1996). The action of mAChRs is 
initiated when ACh binds to the metabotropic receptor that is attached to 
intercellular G-proteins (Ishii & Kurachi, 2006). Following this initial binding, 
mAChRs belonging to the Gq family (i.e., M1, M3, and M5) begin an information 
cascade (Haga, 2013; Ishii & Kurachi, 2006). This signaling pathway starts with 
the activation of phospholipase C (PLC), which initiates the phosphatidylinositol 
4,5-bisphosphate (PIP2) cascade by hydrolyzing PIP2 into diacylglycerol (DAG) 
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and inositol 1,4,5-triphosphate (IP3). Intracellular Ca2+ is mobilized by IP3 and 
protein kinase C (PKC) is activated by DAG and Ca2+ (Berridge, & Irvine, 1984; 
Haga, 2013; Ishii & Kurachi, 2006). The second messenger signaling of mAChRs 
belonging to the Gi/o family (i.e., M2 and M4) differs from receptors of the Gq 
family, in that they inhibit adenylyl cyclase from converting ATP into cyclic AMP, 
which decreases cAMP production and protein kinase A activity (Haga, 2013; 
Ishii & Kurachi, 2006; Nathanson, 2000; Onali & Olianas, 1995; Wess, 1996). In 
addition to decreasing cAMP, mAChRs of the Gi/o type also act on G protein-
coupled potassium (K+) channels, which allows for the efflux of K+ and the 
hyperpolarization of the neuronal membrane, ultimately inhibiting action 
potentials (Haga, 2013; Ishii & Kurachi, 2006).   
In contrast to mAChRs, nAChRs function as ionotropic receptors that act 
as non-selective cation channels (Picciotto, Caldarone, King, & Zachariou, 2000). 
The 11 different neuronal nAChR subtypes are homomeric or heteromeric and 
are composed of five different  or  subunits (Picciotto et al., 2000; Picciotto et 
al., 2012). After the direct binding of ACh to the two  or  subunits, the nAChRs 
open and allow for the influx of Ca2+ and sodium (Na+) into the cytoplasm, 
leading to the depolarization of the post-synaptic neuron (Beker, Weber, Fink, & 
Adams, 2003; Picciotto et al., 2000). nAChRs are dispersed along the post-
synaptic terminal and are also found on the presynaptic terminal, whereas 
nAChRs at the neuromuscular junction are found directly opposite from ACh 
release sites, thus facilitating rapid muscle movement (McGehee, Heath, Gelbert, 
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Devay, & Role, 1995; Pires-Oliveira, Moen, & Akaaboune, 2013; Vidal & 
Changeux, 1993).  
Acetylcholine Innervation 
There is extensive cholinergic innervation because of the essential action 
of ACh at synapses in both the CNS and at the neuromuscular junction of the 
peripheral nervous system (PNS) (Picciotto et al., 2012; Pires-Oliveira et al., 
2013; Ren et al., 2011; Zaborszky et al., 2008). Within the CNS, cholinergic 
neurons are found in various brain nuclei, including the pedunculopontine and 
laterodorsal tegmental areas, the medial habenula, and the basal forebrain 
complex, with widespread projections all over the brain (Picciotto et al., 2012). 
The widespread effects of ACh on behavior are largely due to the diffuse nature 
of the cholinergic system. Interestingly, ACh can function as a neuromodulator in 
the mesolimbic dopamine (DA) system, which is important for reward and 
addiction (Fagen, Mansvelder, Keath, & McGehee, 2003); Mansvelder, De 
Rover, McGehee, & Brussaard, 2003). 
Nicotinic Acetylcholine Receptor Development 
Due to the large number of adolescents who smoke cigarettes (World 
Health Organization [WHO], 2001), it is important to examine the development of 
nicotinic acetylcholine receptors (nAChRs). The expression and functional 
properties of nAChRs often vary across childhood, adolescence, and adulthood 
(Slotkin, 2002), which the expression of some nAChR subunits (e.g., 2 and 3 in 
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the thalamus; 4 in the cortex, thalamus, and brainstem; 7 in the thalamus and 
brainstem; 2 in most brain areas besides the striatum) are constant across 
development (Zhang, Liu, Miao, Gong, & Nordberg, 1998). The widely dispersed 
nAChR 42 that is involved in learning processes, is expressed more in early 
adolescence than adulthood within 33 different brain areas (Doura, Gold, Keller, 
& Perry, 2008). Another nAChR involved in long-term memory, 7 is also 
expressed more in early adolescence than adulthood within 12 different brain 
regions (Doura et al., 2008). DA release via nAChR stimulation in midbrain (i.e., 
ventral striatal) DA neurons is heightened during adolescence when compared to 
adulthood (Azam, Chen, & Leslie, 2007). The latter finding is important because, 
the addictive and reinforcing properties of nicotine involves ventral striatal DA 
release (Corrigall, Franklin, Coen, & Clarke, 1992; Imperato, Mulas, & Di Chiara, 
1986; Nisell, Nomikos, & Svensson, 1995).  
Therefore, many changes in the cholinergic system relating to nAChRs 
are evident in early postnatal development, which some receptor changes occur 
during the adolescent period (Dwyer, McQuown, & Leslie, 2009). Pivotal changes 
in the development of the adolescent cholinergic system may leave this system 
vulnerable to pharmacological insult via certain drugs of abuse (i.e., nicotine). 
Thus, early postnatal and adolescent nicotine exposure may alter brain structure 
and function later on in life (Dwyer et al., 2009). 
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CHAPTER FOUR 
MONOAMINE NEUROTRANSMITTERS 
Introduction 
Monoamine neurotransmitters are characterized as containing one amino 
group attached to an aromatic ring via a two-carbon chain. Specifically, 
catecholamine neurotransmitters are a type of monoamine neurotransmitter that 
contain a catechol and side chain amine (Fernstrorn & Fernstrom, 2007). There 
are three different catecholamine neurotransmitters that are derived from the 
amino acid tyrosine: dopamine (DA), norepinephrine (NE), and epinephrine 
(Fernstrorn & Fernstrom, 2007). An important indolamine synthesized from 
tryptophan is the neurotransmitter serotonin (5-HT) (Fidalgo, Ivanov, & Wood, 
2012). Due to the relevance of these neurotransmitter systems to the present 
study, the catecholamine neurotransmitters DA and NE, as well as the 
indolamine 5-HT, will be discussed in the following sections. 
Dopamine 
The dopaminergic system is known to mediate a number of behaviors, 
including motivation, sleep and wake cycle, learning, mood, cognition, 
movement, addiction, and reward (Alcaro, Huber, & Panksepp, 2007; Dzirasaet 
al., 2006; Gorwood et al., 2012; Plowman & Kleim, 2011; Salamone & Correa, 
2012; Schultz, 2010; Yacubian & Buechel, 2009). Psychological and neurological 
diseases or disorders stemming from dopaminergic dysfunction include 
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Parkinson’s, schizophrenia, Tourette’s syndrome, anxiety, depression, attention-
deficit hyperactivity disorder (ADHD), and substance use disorders (Bisaglia, 
Greggio, Beltramini, & Bubacco, 2013; Buse, Schoenefeld, Münchau, & 
Roessner, 2013; de la Mora, Gallegos-Cari, Arizmendi-García, Marcellino, & 
Fuxe, 2010; del Campo, Chamberlain, Sahakian, & Robbins, 2011; El Mansari et 
al., 2010; Grace, 2010; Schmitt & Reith, 2010). 
Dopamine Synthesis, Release, and Catabolism 
The synthesis of DA begins in the terminal of the presynaptic neuron, 
where the amino acid tyrosine is converted into L-dihydroxyphenylalanine (L-
DOPA) in the presence of tyrosine hydroxylase (Elsworth & Roth, 1997; Feve, 
2012; Haavik & Toska, 1998; Icard-Liepkalns et al., 1993). L-DOPA is then 
converted into DA in the presence of aromatic amino acid decarboxylase (DOPA 
decarboxylase) (Bertoldi, 2014; Elsworth & Roth, 1997; Feve, 2012). Tyrosine 
hydroxylase is the rate-limiting step in the process of DA synthesis and 
production (Elsworth & Roth, 1997; Haavik & Toska, 1998). Vesicular 
monoamine transporters (VMAT), which are found at both dendrites and the axon 
terminals of dopaminergic neurons, store DA in synaptic vesicles (Elsworth & 
Roth, 1997; Henry et al., 1994; Pifl et al., 2014). 
Similar to ACh release, the release of DA and other classical monoamine 
neurotransmitters (e.g., NE and 5-HT) occurs through Ca2+−dependent 
exocytosis into the synaptic cleft (Jaffe, 1998; Sofuoglu & Sewell, 2009; Suedhof, 
2012). Following release from the presynaptic terminal, DA either diffuses into 
18 
the synaptic cleft to bind with DA receptors on the presynaptic or post-synaptic 
terminal, or undergoes reuptake into the presynaptic terminal by DA transporters 
(DAT) (Elsworth & Roth, 1997).   
The process of reuptake by DAT is critical in maintaining consistent intra- 
and extracellular DA levels through the recycling of DA (Elsworth & Roth, 1997; 
Schmitt, Rothman, & Reith, 2013; Vaughan & Foster, 2013). DAT also serves as 
a marker to distinguish dopaminergic neurons through use of ligands and 
antibodies. DAT functions as the site of action for some psychostimulants, such 
as methamphetamine (Elsworth & Roth, 1997; Schmitt et al., 2013; Vaughan & 
Foster, 2013). Once DA is transported into the presynaptic neuron, it is either 
repackaged into vesicles for reuse or is enzymatically degraded into a number of 
different metabolites (Elsworth & Roth, 1997). Catabolism of DA depends on the 
cell type, brain region, and species (Elsworth & Roth, 1997). In the striatum, 
monoamine oxidase (MAO) located on the outer membrane of mitochondria is 
the enzyme that converts DA into 3,4-dihydroxyphenylacetic acid (DOPAC), 
which is then converted into homovanillic acid (HVA) by the enzyme catechol O-
methyltransferase (COMT) located in the cytoplasm (Elsworth & Roth, 1997; 
Goldstein & Lieberman, 1992; Napolitano, Cesura, & Da Prada, 1995). In 
rodents, the main end product of DA degradation is DOPAC, whereas HVA is the 
main DA metabolite in humans (Elsworth & Roth, 1997). 
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Dopamine Receptors and Subtypes 
There are five subtypes of dopamine receptors (i.e., D1-D5), all of which 
are heterotrimeric G protein-coupled receptors (Ares-Santos, Granado, & 
Moratalla, 2013; Beaulieu & Gainetdinov, 2011; Elsworth & Roth, 1997). There 
are two major families of DA receptors, with D1 and D5 receptors belonging to the 
D1-like family, and D2, D3, and D4 receptors belonging to the D2-like family (Ares-
Santos et al., 2013; Beaulieu & Gainetdinov, 2011; Elsworth & Roth, 1997).  
When DA binds to receptors of the D1-like family on the post-synaptic 
membrane, it causes the Gs/olf  proteins to activate adenylyl cyclase, which then 
activates the second messenger molecule cAMP that increases the enzyme 
PKA. Increases in PKA leads to the phosphorylation of neuronal proteins, 
regulation of ion channel functioning, and depolarization of the post-synaptic 
neuron (Ares-Santos et al., 2013; Beaulieu & Gainetdinov, 2011; Vallone, Picetti, 
& Borrelli, 2000).  
When DA binds to receptors of the D2-like family on either the pre- or post-
synaptic membrane, it causes the Gi/o proteins to inhibit activation of adenylyl 
cyclase. Inhibition of adenylyl cyclase leads to the inhibition of cAMP and PKA 
activity, inducing hyperpolarization of the receptor bound neuron (Ares-Santos et 
al., 2013; Beaulieu & Gainetdinov, 2011; Missale et al., 1998; Vallone et al., 
2000). D1 and D2 receptor subtypes are diffuse within the brain and exist in all 
known dopaminergic projections, with high concentrations in the striatum, 
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nucleus accumbens, olfactory bulb, amygdala, frontal cortex, substantia nigra, 
and at lower levels in the hippocampus and ventral tegmental area (Ares-Santos 
et al., 2013; Beaulieu & Gainetdinov, 2011; Gangarossa et al., 2012).  
Dopamine Innervation 
The primary production of DA occurs in the neurons of the substantia 
nigra and ventral tegmental area (Baik, 2013). The neuronal projections from 
these brain areas make up three major dopaminergic pathways: mesolimbic, 
mesocortical, and nigrostriatal (Maharajan, Maharajan, Ravagnan, & Paino, 
2001). The nigrostriatal pathway consists of dopaminergic neurons projecting 
from the substantia nigra to the striatum (Dahlstrom & Fuxe, 1964; Janhunen & 
Ahtee, 2007). The mesocortical pathway consists of dopaminergic neurons 
projecting from the ventral tegmental area to the frontal cortex (Sogabe, 
Yagasaki, Onozawa, & Kawakami, 2013). The mesolimbic pathway is comprised 
of dopaminergic neurons from the ventral tegmental area projecting to the 
nucleus accumbens (Ikemoto, 2007; Koob, 1992; Wise, 1996). The mesolimbic 
pathway, involved in the regulation of reward, motivation, and emotion, is subject 
to physiological changes following repeated exposure to addictive substances 
(Baik, 2013; Nestler & Carlezon, 2006). The changes to the mesolimbic system 
produced by certain addictive drugs are thought to be responsible for drug 
dependence (Thomas, Kalivas, & Shaham, 2008). 
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Dopaminergic System Development 
Development of the dopaminergic system is important to examine 
because stimulants like methamphetamine bind to vesicular DA transporters, 
causing the release of DA into the synaptic cleft (Courtney & Ray, 2014). The 
expression of DA receptor subtypes varies across developmental periods (Spear, 
2010). At birth, D1 and D2 receptors are present in the striatum, but by PD 15 D1 
receptors begin to increase in density (Gelbard, Teicher, Faedda, & Baldessarini, 
1989). By adulthood, there is a three-fold increase in D1 receptors, compared to 
D2 receptors in the striatum (Gelbard et al., 1989). D1 receptor expression peaks 
in the striatum around PD 40 and then stabilizes to adult levels around PD 60 
(Gelbard et al., 1989; Teicher et al., 1995). This increase in D1 receptor 
expression may be important for the early development of the basal ganglia 
(Meng, Ozawa, Itoh, & Takashima, 1999).  
D2 receptors also increase in density across early development and 
adolescence, peaking around PD 21-28, followed by a reduction in receptor 
density going into adulthood (Demotes-Mainard, Henry, Jeantet, Arsaut, & 
Arnauld, 1996; Murrin & Zeng, 1986; Tarazi, Tomasini, & Baldessarini, 1998). 
Within the striatum, D2 receptors develop at the same rate, but with less density 
than D1 receptors (Andersen et al., 2000; Teicher et al., 1995). Within the limbic 
system, D3 receptor expression is observed as early as PD3 and increases in 
receptor density occur through adulthood (Demotes-Mainard et al., 1996; Fallon, 
Riley, Sipe, & Moore, 1978). Further, DAT levels are increased during 
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adolescence when compared to adulthood (Meng et al., 1999). Innervation of DA 
neurons from the striatum and midbrain to the prefrontal cortex peaks during 
adolescence (Benes, Taylor & Cunningham, 2000). Thus, alterations in the 
dopaminergic system may cause adolescents to express heightened reward 
sensitivity compared to adults, which leaves this group particularly vulnerable to 
substance use (Geier, 2013). 
Norepinephrine 
Within the CNS, NE is involved in a variety of behavioral outcomes, 
including attention, arousal, cognition, impulsivity, memory, emotion, stress, drug 
seeking, and reward (Flavin & Winder, 2013; Goddard et al., 2010; Hamon & 
Blier, 2013; Howells, Stein, & Russell, 2012; Logue & Gould, 2014; Pattij & 
Vanderschuren, 2008; Sofuoglu & Sewell, 2009; Tully & Bolshakov, 2010). 
Dysfunction of the noradrenergic system results in various disorders and 
diseases, ranging from ADHD, major depressive disorder, anxiety disorders, 
bipolar disorder, to addiction and substance use disorders (Belujon & Grace, 
2011; El Mansari et al., 2010; Fitzgerald, 2013; Goddard et al., 2010; Park, 
Caballero, & Omidian, 2014; Pervanidou, 2008; Sofuoglu & Sewell, 2009; Swan, 
2010). 
Norepinephrine Synthesis, Release, and Catabolism 
NE is synthesized from DA in the presence of dopamine-β-hydroxylase 
(Ressler & Nemeroff, 1999; Sofuoglu & Sewell, 2009). The synthesis of NE can 
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occur in either DA containing vesicles or NE is transferred from the cytoplasm 
into synaptic vesicles by VMAT and is stored in the axon terminal (Ressler & 
Nemeroff, 1999; Sofuoglu & Sewell, 2009).   
Following Ca2+−dependent exocytosis, NE undergoes reuptake by the NE 
transporter (NET) and is reused, or MAO enzymatically destroys NE (Bönisch, & 
Brüss, 2006; Ressler & Nemeroff, 1999; Sofuoglu & Sewell, 2009). MAO 
converts NE into aldehyde, which is then converted into either 3,4-
dihydroxyphenylglycol (DHPG) or 3,4-dihydroxymandelic acid (DHMA) by 
dehydrogenase or reductase enzymes (Ressler & Nemeroff, 1999). COMT 
continues to catabolize these compounds, especially when NE levels are high 
(Huotari et al., 2002; Ressler & Nemeroff, 1999). 
Norepinephrine Receptors and Subtypes 
Noradrenergic receptors can be activated by both NE and epinephrine, 
and are G protein-coupled receptors that exist in two major family types,  or  
receptors (Bylund et al., 1994). The  receptors are divided into 1 and 2 
adrenergic families (Bylund et al., 1994). The 1 receptor family is divided into 
1A, 1B, and 1D subtypes, whereas the 2 adrenergic family is divided into 2A, 
2B, and 2C subtypes (Bylund et al., 1994; Oh et al., 2013; Segura et al, 2010). 
The 1 family is mostly comprised of post-synaptic excitatory Gq protein coupled 
receptors, which activates PLC (Sofuoglu & Sewell, 2009). The 2 
adrenoreceptors are located on pre- and post-synaptic terminals and are coupled 
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to the Gi/o protein, which inhibits adenylyl cyclase (Sofuoglu & Sewell, 2009). The 
inhibition of adenylyl cyclase results in a reduction of cAMP production, causing 
hyperpolarization of the neuronal membrane and reduced neuronal firing 
(Stojilkovic, 2012).  
The  adrenoreceptors are divided into 1, 2, and 3 subtypes and are 
coupled to the Gs protein, which activates adenylyl cyclase (Sofuoglu & Sewell, 
2009). Activation of adenylyl cyclase results in the conversion of ATP into cAMP, 
leading to changes in ion channels and subsequent depolarization of the 
neuronal membrane (Stojilkovic, 2012).  
Norepinephrine Innervation 
Noradrenergic nuclei are primarily found in the locus coeruleus of the 
brain stem and project to nearly every area of the brain (Szabadi, 2013). In 
comparison to the dopaminergic system, the DA projections from the ventral 
tegmental area and substantia nigra are relatively limited when compared to NE 
neuronal projections extending from the locus coeruleus (Ressler & Nemeroff, 
1999).  
Noradrenergic System Development 
Like other neurotransmitter systems, the NE system experiences changes 
in NE release and receptor expression throughout development. For example, 
social stress occurring during early adolescence (i.e., PD 28), but not mid-
adolescence (i.e., PD 42) produces heightened spontaneous locus coeruleus 
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discharge, and attenuates responsiveness to sensory stimuli (Bingham et al., 
2011). Cerebral -adrenoreceptor expression rapidly increases between PD 10 
and PD 21, after which receptor expression remains fairly constant up to mid-
adolescence (i.e., PD 42), but then quickly attenuates thereafter (Pittman, 
Minneman, & Molinoff, 1980). In contrast, cerebellar -adrenoreceptor 
expression rises slowly from PD 5 to PD 42, where receptor levels are constant 
up to at least 6 months of age (Pittman et al., 1980). Due to the remodeling that 
the noradrenergic system undergoes during development and adolescence, in 
particular, it is possible that adolescent stimulant exposure produces 
fundamental changes in the NE system during this vulnerable time period 
(Trauth, Seidler, Ali, & Slotkin, 2001). Adolescent stimulant exposure to nicotine 
or methamphetamine may fundamentally alter noradrenergic and dopaminergic 
systems, potentially resulting in heightened reward sensitivity and susceptibility 
to drug abuse (Trauth et al., 2001). 
Serotonin 
5-HT is a monoamine found in both the PNS and CNS (Fidalgo et al., 
2012). In the PNS, roughly 95% of the 5-HT is produced within enterochromaffin 
cells of the digestive tract (Gershon, 2004). In the CNS, 5-HT is readily produced 
from neurons originating in the raphe nuclei of the brain stem (Adell, Celada, 
Abellán, & Artigas, 2002). 5-HT is involved in a wide variety of 
neuropsychological processes, including cognition, decision-making, learning, 
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memory, appetite, sleep, sexual desire, social behavior, mood, and emotion 
(Cowen & Sherwood, 2013; Homberg, 2012; Lam, Garfield, Marston, Shaw, & 
Heisler, 2010; Kiser, Steemers, Branchi, & Homberg, 2012; Menese & Liy-
Salmeron, 2012; Montgomery, Baldwin, & Riley, 2002; Monti, 2011). Dysfunction 
of the serotonergic system is related to a number of disorders, such as 
Parkinson’s disease, Alzheimer’s disease, schizophrenia, depression, anxiety, 
phobias, panic attacks, post-traumatic stress disorder, antisocial behavior, drug 
abuse, addiction, and substance use (Eggers, 2013; Fernandez & Gaspar, 2012; 
Huot & Fox, 2013; Kirby, Zeeb, & Winstanley, 2011; Meltzer, 1989; Nordquist, & 
Oreland, 2010; Rodríguez, Noristani, & Verkhratsky, 2012). 
Serotonin Synthesis, Release, and Catabolism 
The synthesis of 5-HT can occur in either the soma or axon terminal of 
serotonergic neurons (Daszuta, Hery, & Faudon, 1984; Daszuta, Faudon, & 
Hery, 1984). 5-HT is derived from tryptophan, which is obtained from the diet 
(Leathwood, 1987). Tryptophan is converted into 5-hydroxy-l-tryptophan (5-HTP) 
by the enzyme l-tryptophan-5-monooxygenase hydroxylase (tryptophan 
hydroxylase), which serves as the rate-limiting step in the biosynthesis of 
serotonin (Boadle-Biber, 1993; Fidalgo, et al., 2012; Leathwood, 1987; Tyce, 
1990). 5-HTP is then converted into 5-HT by the enzyme aromatic-l-amino-acid 
decarboxylase (DOPA decarboxylase) (Boadle-Biber, 1993; Fidalgo, et al., 2012; 
Leathwood, 1987; Tyce, 1990). Newly formed 5-HT is then packaged into 
secretory synaptic vesicles for protection against degradation by MAO and to 
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await release into the synaptic cleft via Ca2+−dependent exocytosis (Jorgensen, 
Christensen, & Gether, 2014; Tamir, & Gershon, 1990). 
Following release into the synaptic cleft, 5-HT either binds to pre- or post-
synaptic 5-HT receptors and/or is removed from the synaptic cleft by the 5-HT 
transporter (SERT) through active reuptake into the presynaptic terminal (Fuller, 
1986; Ni & Watts, 2006; Südhof, 2008). After reuptake, 5-HT is either 
repackaged or undergoes enzymatic degradation (Duncan, Johnson, & Xiao-
Ming, 2012). The removal of 5-HT from the synaptic cleft is essential to avoid 
potentially deadly levels of extracellular 5-HT (i.e., serotonin syndrome) (Squires, 
Talbot, Rubakhin, & Sweedler, 2007). 5-HT catabolism within the CNS begins 
when MAO converts 5-HT into 5-hydroxy-3-indole acetaldehyde (5-HAIL), which 
is further broken down into 5-hydroxy-3-indoleacetic acid (5-HIAA) by aldehyde 
dehydrogenase (Squires et al., 2006).   
Serotonin Receptors and Subtypes 
5-HT receptors are classified into seven major types: 5-HT1, 5-HT2, 5-HT3, 
5-HT4, 5-HT5, 5-HT6, and 5-HT7 (Berger, Gray, & Roth, 2009; Hoyer, Hannon, & 
Martin, 2002). All seven types, with the exception of the 5-HT3 ligand-gated ion 
channel, are G-protein-coupled receptors (Hoyer et al., 1994; Nichols & Nichols, 
2008). Specifically, the 5-HT1 family (i.e., 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-
HT1F, 5-HT5A, and 5-HT5B) are Gi/o coupled receptors that, when activated, cause 
the inhibition of adenylyl cyclase and decrease the production of cAMP (Hamel, 
1999; Hartig, Branchek, & Weinshank, 1992; Kobilka et al., 1987; Lovenberg et 
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al., 1993; Noda, Higashida, Aoki, & Wada, 2004; Wacker et al., 2013; Watts & 
Neve, 2005; Wisden et al., 1993). The 5-HT2 family (i.e., 5-HT2A, 5-HT2B, and 5-
HT2C) are Gq/11 coupled receptors that cause the hydrolysis of membrane 
phosphoinositides into DAG and inositol phosphates (Belmer et al., 2014; 
Chambers & Nichols, 2002; Facchinetti, & Russo de Boland, 2001; Huidobro-
Toro, Valenzuela, & Harris, 1996). DAG and inositol phosphates then work as 
signaling molecules that ultimately lead to PKC activation or elevation of 
intracellular calcium, respectively (Nichols & Nichols, 2008). The 5-HT4, 5-HT6, 
and 5-HT7 families are Gs coupled receptors that, when bound to lead to adenylyl 
cyclase activation, result in the conversion of ATP into cAMP (Hamblin, Guthrie, 
Kohen, & Heidmann, 1998; Kang et al., 2005; Nedi, White, Coupar, & Irving, 
2011). The 5-HT3 receptor is a ligand-gated ion channel composed of five 
subtypes (i.e., 5-HT3A, 5-HT3B, 5-HT3C, 5-HT3D, and 5-HT3E) (Massoura, Dover, 
Newman, & Barnes, 2011; Takimoto et al., 2014). When 5-HT binds to the 5-HT3 
receptor, an excitatory post-synaptic potential occurs on the neuronal membrane 
(Barnes, Hales, Lummis, & Peters, 2009; Connolly & Wafford, 2004).  
Serotonin Innervation 
The brain is innervated by serotonergic neurons that primarily arise from 
raphe nuclei of the brain stem, and a smaller amount of neurons from the lateral 
reticular formation (Hornung, 2003). Serotonergic neurons extending from the 
raphe nuclei can be divided into a rostral group, which projects to areas of the 
mesencephalon, rostral pons, and forebrain, and a caudal group, which projects 
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to the caudal pons, caudal medulla oblongata, brain stem, and spinal cord 
(Hornung, 2003; Moore, Halaris, & Jones, 1978). The rostral projections account 
for 85% of 5-HT within the brain, most of which project to the ventral tegmental 
area and interpeduncular nucleus (Halliday & Tork, 1986; Hornung, 2003). 
Serotonergic System Development 
In the rodent brain, 5-HT levels peak in early development (i.e., PD 21-30) 
and gradually decline to adult levels (Hedner, Lundell, Breese, Mueller, & 
Hedner, 1986; Murrin, Sanders, & Bylund, 2007; Toth & Fekete, 1985). The 
number of 5-HT synapses within the basal forebrain increases from birth to PD 
14, followed by a rapid decline during early adolescence (Dinopoulos, Dori, & 
Parnavelas, 1997; Dori, Dinopoulos, & Parnavelas, 1998). 5-HT receptor 
subtypes are also expressed in different time periods and brain regions, with 
peaks either at birth or just before adolescence (Bar-Peled et al., 1991; Morilak & 
Ciaranello, 1993; Vizuete et al., 1997). For example, cortical 5-HT2A receptors 
(Morilak & Ciaranello, 1993), as well as striatal and hippocampal 5-HT7 receptors 
(Vizuete et al., 1997) are in greatest numbers immediately before adolescence 
and steadily decline to adult levels, whereas 5-HT1A receptors reach peak 
expression at birth, but rapidly decline across adolescence and into adulthood 
(Bar-Peled et al., 1991; Burnet, Eastwood, & Harrison, 1994; Daval, Vergé, 
Basbaum, Bourgoin, & Hamon, 1987). 5-HT turnover in the nucleus accumbens 
also shows ontogenetic differences, as 5-HT turnover is 4 times less during 
adolescence than during the preweanling period or adulthood (Spear, 2000). It is 
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possible that decreased serotonergic activity across adolescence contributes to 
heightened anxiety and hypersensitivity to mild stressors (Depue & Spoont, 
1986). It is clear the 5-HT system undergoes many changes beginning at birth, 
through childhood, adolescence, and into adulthood. Thus, the adolescent 
serotonergic system remains increasingly vulnerable to pharmacological induced 
neuronal changes (Chambers, Taylor, & Potenza, 2003). 
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CHAPTER FIVE  
NICOTINE 
Introduction 
 Nicotine is a psychostimulant drug with strong addictive properties. 
Nicotine is used in a variety of products, such as cigarettes, chewing tobacco, 
snuff, nicotine gum or patches, and most recently electronic cigarettes 
(Fagerstrom, Schneider, & Lunell, 1993; Farsalinos & Polosa, 2014; Hoffmann & 
Hoffmann, 1997; Puri, Chaudhary, Srivastava, Tiwari, 2013). Of the various 
nicotine products, cigarettes are the most popular, with worldwide cigarette 
smoking resulting in about 6 million deaths a year, and is predicted to be the 
cause of nearly 1 billion deaths within the 21st century (Farsalinos & Polosa, 
2014; Yach, 2014). Lung cancer remains the leading cause of cancer related 
deaths, in which 80-90% of lung cancer deaths are attributed to cigarette 
smoking (Centers for Disease Control and Prevention [CDC], 2008; Henley et al., 
2014). In addition, cigarette smoking remains one of the most difficult stimulant 
addictions to treat, with a relapse rate of around 90-95% in unaided quit attempts 
within one year of the cessation date (Bancej, O’Loughlin, Platt, Paradis, & 
Gervais, 2007; Hughes, Keely, & Naud, 2004; Lydon, Wilson, Child, & Geier, 
2014; Van Zundert, Ferguson, Shiffman, & Engels, 2012). 
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Mechanism of Action and Pharmacokinetics 
When smoke particles containing nicotine are inhaled, nicotine is rapidly 
absorbed through the lungs and into the bloodstream, where it quickly moves to 
the brain (Benowitz, 2010; Weinberger & Sofuoglu, 2009). After crossing the 
blood-brain barrier, nicotine binds to nAChRs (Clader & Yuguang, 2005; Dajas-
Bailador & Wonnacott, 2004; Dani & Bertrand, 2007). Increased ACh release 
results in augmented release of other neurotransmitters, such as DA 
(Benowitz, 2010). Nicotine-induced DA release from ventral tegmental area 
neurons projecting to the nucleus accumbens are a pivotal component in 
nicotine-induced pleasure and reward (Dani & De Biasi, 2001; Nestler, 2005; 
Picciotto & Corrigall, 2002).  
Nicotine augments the release of glutamate in the VTA, which promotes 
the release of DA in the nucleus accmubens (Mansvelder & McGehee, 2000; 
2002). Conversely, γ-aminobutyric acid (GABA) release in the VTA inhibits DA 
release in the nucleus accmubens (Mansvelder & McGehee, 2000; 2002). 
Continual binding of nicotine causes some of the nicotinic ACh receptors to 
become desensitized (Mansvelder & McGehee, 2000; 2002). This desensitization 
results in a diminished inhibition of DA release, while glutamate continues to 
augment DA release (Benowitz, 2010; Mansvelder & McGehee, 2000; 2002).  
Behavioral and Physiological Effects 
Following cigarette smoking, a smoker will typically feel sensations of 
stimulation and pleasure, as well as a reduction in stress and anxiety (Benowitz, 
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2009). Additional behavioral effects of nicotine include augmented finger tapping, 
focused and sustained attention, as well as improved reaction time, recognition 
memory, and reasoning (Heishman, 1999). Physiological effects of nicotine 
include decreases in body weight, as well as increases in heart rate and blood 
pressure (Heishman, 1999; Omvik, 1996). When a smoker stops smoking, they 
will often experience aversive withdrawal symptoms, such as anxiety, difficulty 
concentrating, irritability, and restlessness (Benowitz, 2010; Heishman, 1999). 
Therefore, smokers need nicotine to relieve aversive symptoms during 
withdrawal (Jarvik, 1991). It is believed that chronic cigarette use is partly due to 
this negative reinforcement (Jarvik, 1991). 
Adolescent Cigarette Smoking 
Cigarette smoking is most likely to begin during adolescence (Chen & 
Kandel, 1995; Lantz, 2003). Among adult smokers within the United States, 
nearly 90% of them began smoking before the age of 18 (CDC, 2013). The 
prevalence rates for tobacco product use among middle school and high school 
students are 6.7% and 23.3%, respectively (CDC, 2013). Additionally, the rate of 
increase in cigarette smoking among adolescents is striking, with 3,000 American 
children under the age of 18 beginning to smoke each day (Slotkin, 2002). This is 
particularly concerning given that smoking is the main causal factor in nearly 
30% of all cancer-related deaths (CDC, 2008; Henley et al., 2014). 
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Nicotine as a Gateway Drug 
Gateway theories of drug addiction propose that psychological and 
neurobiological mechanisms of less deleterious drugs (e.g., nicotine or alcohol) 
function as a gateway to more dangerous hard drugs of abuse (e.g., 
methamphetamine or cocaine) (Kandel & Faust, 1975; Lindsay & Rainey, 1997; 
Nolley & Kelley, 2007; Weinberger & Sofuoglu, 2009). Indeed, among U.S. adults 
(i.e., ages 18 to 34) who used cocaine in their lifetime, 87.9% smoked cigarettes 
before their cocaine use (Kandel & Kandel, 2014). In contrast, 5.7% of adults 
used cocaine and cigarettes at the same time, 3.5% of adults used cocaine first, 
and 2.9% of cocaine users never smoked cigarettes (Kandel & Kandel, 2014). 
With the recent rise in electronic cigarette use, especially among adolescents, 
some researchers are suggesting the possibility of electronic cigarettes 
functioning as a gateway for more traditional tobacco cigarettes (Bell & Keane, 
2014).  
Although the gateway theory of drug addiction is mostly accepted in 
popular culture, it still remains debated within academic literature and 
researchers in this field are careful not to express causal relationships between 
the progressions from soft drugs to hard drugs (Bell & Keane, 2014). Rather, the 
correlational relationship between this progression is typically expressed as 
being strongly statistically linked (Lindsay & Rainey, 1997). In terms of the 
gateway hypothesis, epidemiological studies are important for establishing the 
sequence in which certain drugs may be used; however, it is imperative to 
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employ animal models of addiction to make causal assertions about the 
progression of one drug to another (Kandel & Kandel, 2014). 
Adolescent Animal Studies 
Adolescent animal models of smoking are essential to determine how 
nicotine exposure can alter adolescent brain structure, functioning, and resulting 
behavior. For example, adolescent nicotine exposure alters brain neurochemistry 
when compared to adults (Shearman, Fallon, Sershen, & Lajtha, 2008). 
Specifically, adolescent nicotine exposure induces greater extracellular levels of 
dopamine and 5-HT in the nucleus accumbens (Shearman et al., 2008). 
Comparing nicotine withdrawal in adolescent and adult rodents, adolescent 
rodents show significantly less mecamylamine-induced withdrawal signs than 
adults (Kota, Martin, & Damaj, 2008; O'Dell, Bruijnzeel, Ghozland, Markrou, & 
Koob, 2004). These results suggest that adolescents display decreased 
sensitivity to nicotine withdrawal, which by minimizing the aversive effects of 
nicotine abstinence may maximize the reinforcing effects of nicotine during the 
adolescent period (Kota et al., 2008; O'Dell et al., 2004). Further comparing 
adolescent and adult nicotine-pretreated rodents, adolescent-pretreated rodents 
display heightened nicotine reward sensitivity in adulthood, as compared to adult-
pretreated rodents tested on conditioned place preference (CPP) task (Adriani, 
Deroche-Gamonet, Le Moal, Laviola, & Piazza, 2006; Kota et al., 2008). 
Additionally, a single nicotine conditioning trial can elicit a CPP response in 
adolescents, but not adults, suggesting that adolescents form associations more 
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readily (Belluzzi, Lee, Oliff, & Leslie, 2004; Brielmaier, McDonald, & Smith, 
2007). The results from these CPP experiments indicate that adolescent smokers 
may be at a greater risk for nicotine addiction than individuals who start smoking 
later in life (Adriani et al., 2006; Belluzzi et al., 2004; Brielmaier et al., 2007; Kota 
et al., 2008). Similarly, comparing the self-administration of nicotine between 
adolescent and adult rats, adolescent rats acquire more quickly and take higher 
amounts of nicotine than adult rats, suggesting that nicotine is more reinforcing in 
adolescent compared to adult rats (Chen, Matta, & Sharp, 2007; Levin, Rezvani, 
Montoya, Rose, & Swartzwelder, 2003; but see Shram, Funk, Li, & Lê, 2008). 
Lastly, adolescent mice have a greater preference for a nicotine and sucrose 
solution than adults, further suggesting a heightened vulnerability to nicotine 
(Adriani, Macrì, Pacifici, & Laviola, 2002). 
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CHAPTER SIX 
METHAMPHETAMINE 
Introduction 
Methamphetamine hydrochloride is a highly addictive and abused 
psychostimulant classified as a schedule II controlled substance within the United 
States (Calcaterra & Binswanger, 2013; Drug Enforcement Administration [DEA], 
U.S. Department of Justice, 2003). methamphetamine is often sold illicitly and 
used recreationally, with estimates of approximately 25 million methamphetamine 
abusers worldwide (Panenka et al., 2013). This prevalence rate is greater for 
both cocaine (i.e., ~14 million) and heroin (i.e., ~11 million) abusers (Panenka et 
al., 2013).   
Mechanism of Action and Pharmacokinetics 
Methamphetamine enters the body typically through the lungs via 
inhalation of smoke particles, although methamphetamine can be taken by a 
number of routes, including sublingual, rectal, intranasal, intravenous injection, 
subcutaneous injection, or solubilized and consumed orally as a liquid, but the 
latter routes are not as common (Courtney & Ray, 2014; Novak & Kral, 2011; 
Rusyniak, 2013). Once in the blood stream, methamphetamine travels to the 
brain where it readily crosses the blood-brain barrier, due to its lipophilic structure 
(Courtney & Ray, 2014; Rusyniak, 2013; Vearrier, Greenberg, Miller, Okaneku, 
Haggerty, 2012).  
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Within the CNS, methamphetamine functions as an indirect agonist, which 
acts on DA, NE, 5-HT, and to a lesser extent glutamate neurotransmitter systems 
in the nucleus accumbens (Cruickshank & Dyer, 2009; Nordahl, Salo, & Leamon, 
2003). The impact of methamphetamine on reward occurs through an increase of 
DA in the nucleus accumbens (Wise & Bozarth, 1984). Due to a similar molecular 
structure, methamphetamine substitutes for the monoamine neurotransmitters 
DA, NE, and 5-HT at their respective transporter sites (i.e., DAT, NET, and 
SERT) (Cruickshank & Dyer, 2009; Rothman et al., 2001). Once in the cell, 
methamphetamine induces changes in pH levels and the vesicle proton gradient, 
so that newly synthesized monoamine neurotransmitter accumulates in the 
cytosol of the presynaptic neuron (Courtney & Ray, 2014; Cruickshank & Dyer, 
2009; Sulzer, Sonders, Poulsen, & Galli, 2005). Additionally, methamphetamine 
alters the functioning of VMAT, aiding in the cytoplasmic accumulation of 
monoamine neurotransmitters (Halpin, Collins, & Yamamoto, 2014). 
Accumulation of excess monoamine neurotransmitters in the cytosol causes 
DAT, NET, and SERT to actively pump DA, NE, or 5-HT into the synaptic cleft, 
thus methamphetamine reverses the endogenous roles of these monoamine 
transporters (Courtney & Ray, 2014; Cruickshank & Dyer, 2009; Rusyniak, 2013; 
Sulzer et al., 2005; Vearrier et al., 2012).  
In addition to increasing the release of monoamine neurotransmitters, 
methamphetamine also attenuates the metabolism of DA, NE, and 5-HT by 
inhibiting the enzyme MAO (Cruickshank & Dyer, 2009; Sulzer et al., 2005). This 
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action produces a rapid accumulation of monoamine neurotransmitters in the 
brain because MAO is inhibited from catabolizing DA, NE, and 5-HT (Meredith, 
Jaffe, Ang-Lee, & Saxon, 2005; Rusyniak, 2013). Methamphetamine has longer 
half-life of about 12 h, whereas cocaine has a shorter half-life (i.e., 90 min) 
(Rawson et al., 2000).  
Behavioral and Physiological Effects 
Acute effects of methamphetamine are generally linked with feelings of 
euphoria, invincibility, increased energy, wakefulness, and heightened sexual 
experiences (Cruickshank & Dyer, 2009; Russell et al., 2008; Vearrier et al., 
2012). However, continued methamphetamine use can become harmful and 
typically effects physical and psychological processes, causing confusion, 
tremors, convulsions, anxiety, aggressiveness, hallucinations, and paranoia 
(Russell et al., 2008; Vearrier et al., 2012). Prolonged methamphetamine use 
results in increased cravings leading to chronic use (Russell et al., 2008; Vearrier 
et al., 2012). The effects of chronic methamphetamine use are characterized by 
neurotoxicity and major depressive disorder, with the potential for suicidal 
ideation and action (Russell et al., 2008; Vearrier et al., 2012). 
Methamphetamine abuse may result in a wide range of complications, 
such as cardiovascular, dermatological, hematological, gastrointestinal, 
genitourinary, musculoskeletal, neurological, psychiatric, and pulmonary 
problems, as well as renal failure, perinatal maternal death, and premature death 
(Russell et al., 2008; Vearrier et al., 2012). In addition to these complications, 
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methamphetamine addiction also serves as a serious public health problem 
because of the crime and violence associated with methamphetamine abuse 
(Vearrier et al., 2012). Due to the highly addictive nature of methamphetamine, 
negative treatment outcomes and relapse are often expected for 
methamphetamine addictions (Vearrier et al., 2012). Many of the psychosocial 
interventions for methamphetamine dependence are riddled with poor entrance 
and retention rates (Shearer, 2007). There currently are no 
psychopharmacological treatments approved by the U.S Food and Drug 
Administration for methamphetamine dependence, although several medications 
are currently under study (Courtney & Ray, 2014).  
Adolescent Methamphetamine Use 
In terms of the United States, a 2012 report from the Substance Abuse 
and Mental Health Services Administration (SAMHSA) found that approximately 
12 million (~ 4.7 %) Americans aged 12 and older have tried methamphetamine 
in their lifetime (Courtney & Ray, 2014; SAMHSA, 2013). Additionally, about 1.2 
million have reported using methamphetamine in the last year, and around 
440,000 have used methamphetamine in the last month (Courtney & Ray, 2014; 
SAMHSA, 2013). Among high school students, a Monitoring the Future survey 
found that 1.6% had used methamphetamine in 2010 (Panenka et al., 2013). 
Additionally, adolescent methamphetamine use is particularly common in the 
western regions of the United States and Canada (Gruenewald, Johnson, 
Ponicki, Remer, & Lascala, 2010; Rawson, Anglin, & Ling, 2002).   
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Methamphetamine and Nicotine 
Simultaneous psychostimulant and nicotine use is highly prevalent (Brecht 
et al., 2004). Indeed, cocaine users reported increased rates of cigarette use (70-
80%) and nicotine dependence (50%) compared to the general population (22% 
and 13%, respectively) (Grant, Hasin, Chou, Stinson, & Dawson, 2004; Kalman, 
Morissette, & George, 2005; Patkar et al., 2006). The co-morbidity rates of 
methamphetamine use and cigarette smoking are even higher (87-92%) (Baker 
et al., 2004; Grant et al., 2007).  
In regards to cigarette smoking and treatment of other stimulant addictions 
(e.g., cocaine or methamphetamine), it is clear users are motivated to quit; 
however, smoking cessation rates are low (~12 %) (Campbell, Wander, Stark, & 
Holbert, 1995; Weinberger & Sofuoglu, 2009). Due to mixed reports, it is unclear 
whether concurrent cigarette smoking and other stimulant use is detrimental to 
drug treatment outcomes (Weinberger & Sofuoglu, 2009). Some clinical reports 
suggest that use of nicotine-containing products may facilitate the onset of 
methamphetamine relapse in addicts, thus the management of nicotine intake 
should be considered in clinical settings (Berry et al., 2012). Similarly, self-report 
studies show that cocaine-dependent individuals report stronger cocaine 
cravings following nicotine treatment (Reid, Mickalian, Delucchi, Hall, & Berger, 
1998), whereas the nicotine antagonist, mecamylamine, reduces cocaine craving 
in cocaine-dependent individuals (Reid, Mickalian, Delucchi, & Berger, 1999). In 
contrast, other clinical reports suggest concern that cessation of nicotine-
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containing products may increase the risk of relapse to other stimulants, such as 
methamphetamine or cocaine (Weinberger & Sofuoglu, 2009). The potential for 
cigarette smoking to produce neurological changes that facilitate the initiation 
and augmentation of methamphetamine or cocaine use is concerning. In order to 
further investigate this relationship, it is necessary to turn to animal models of 
addiction. 
Psychostimulant and Nicotine Animal Studies 
Periadolescent rats pretreated with nicotine for 7 days and subsequently 
challenged with cocaine or amphetamine on the following day, display 
heightened locomotor activity when compared to adult rats (Collins & 
Izenwasser, 2004; Collins, Montano, & Izenwasser, 2004). These results suggest 
that adolescent nicotine exposure creates a greater risk for cocaine or 
amphetamine abuse in adolescence as compared to adulthood (Collins & 
Izenwasser, 2004; Collins et al., 2004). Relatedly, adolescent nicotine 
pretreatment enhances the acquisition of cocaine self-administration when 
compared to adults, further indicating the susceptibility of the adolescent brain to 
the effects of nicotine on subsequent stimulant use (McQuown, Belluzzi, & Leslie, 
2007). Rats treated with nicotine for 10 days during adolescence engaged in 
more cocaine seeking following cocaine-induced reinstatement in adulthood, 
suggesting that nicotine exposure in adolescence may alter the vulnerability for 
cocaine relapse in adulthood (Anker, & Carroll, 2011).  
43 
When considering the role of nicotine treatment on methamphetamine 
self-administration, rats that received nicotine treatment in adolescence through 
adulthood received more methamphetamine infusions when compared to rats 
treated with saline (Pipkin et al., 2014). Thus, continuous nicotine exposure 
beginning in adolescence through adulthood enhances the reinforcing effects of 
methamphetamine. In addition, nicotine-pretreated adolescent rats received 
more methamphetamine intake in adulthood than saline-pretreated adolescent 
rats (Pipkin et al., 2014). Thus, adolescent nicotine pre-exposure increases the 
reward potential of methamphetamine in adulthood.  
In regards to the role of nicotine on methamphetamine relapse, nicotine 
treatment in adolescent rats does not alter methamphetamine-induced 
reinstatement in adults (Pipkin et al., 2014). Thus, adolescent nicotine exposure 
does not affect methamphetamine seeking and relapse in adulthood. In contrast, 
5 days of nicotine treatment during extinction attenuates methamphetamine 
reinstatement in adult rats, suggesting that in certain experimental conditions, 
nicotine treatment reduces methamphetamine seeking and attenuate the risks 
associated with relapse (Hiranita, Anggadiredja, Fujisaki, Wantanabe, & 
Yamamoto, 2004; Hiranita, Nawata, Sakimura, Anggadiredja, & Yamamoto, 
2006; Hiranita, Nawata, Sakimura, & Yamamoto, 2008). The difference in 
methamphetamine reinstatement findings may be due to age and/or duration of 
nicotine treatment. Despite opposing directions between nicotine and 
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methamphetamine self-administration and reinstatement data, it is clear that a 
relationship between the two drugs exists. 
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CHAPTER SEVEN 
SELF-ADMINISTRATION  
Introduction 
The drug self-administration paradigm has been widely used since the 
1960’s and functions as an operant conditioning procedure used to study reward 
and addiction behavior (Deneau, Yangita, & Seevers, 1969; Thompson & 
Schuster, 1964; Weeks, 1962). Self-administration examines whether the effects 
of a drug will reinforce a certain behavior, such as pressing a lever for a drug 
injection (Balster & Schuster, 1973; Stoops, 2008).   
Self-administration can be used on animal or human subjects and can 
utilize different routes of administration, such as insufflation, oral ingestion, 
inhalation, or intragastric infusion, as well as intramuscular, intravenous, 
intraperitoneal, or intracerebral injections (Gardner, 2000; Panlilio & Goldberg, 
2007). Intravenous injections and oral ingestion are the most typically used 
routes of administration (Gardner, 2000; Panlilio & Goldberg, 2007); however, 
intravenous injections and inhalation are the faster routes of delivery and, 
therefore, produce stronger reinforced behaviors (Gardner, 2000; Panlilio & 
Goldberg, 2007).  
The drug self-administration paradigm relies on operant conditioning 
principles, with the main assumption that drugs serve as reinforcers, thus 
increasing the likelihood of a certain behavior that is paired with the effects of a 
drug (Edwards & Koob, 2013; Panlilio & Goldberg, 2007). The response and 
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reinforcement relationship (i.e. pushing a lever for a drug injection) can be further 
manipulated by using different schedules of reinforcement, such as requiring a 
certain number of responses or amount of time to pass before the subject 
receives the reinforcing effects of the drug (Haney & Spealman, 2008; Spealman 
& Goldberg, 1978; Stoops, 2008). One of the most simple and extensively used 
schedules of reinforcement is continuous reinforcement, where the subject is 
reinforced for every response given (Domjan, 2005; Gál & Gyertyán, 2003; 
Minhas & Len, 2014; Panlilio & Goldberg, 2007). This schedule is results in a 
dose-dependent manner; with higher doses resulting in less frequent responses 
(Panlilio & Goldberg, 2007). Continuous reinforcement does not typically 
correspond to behavior in a natural context, because an oragnism must often 
work for a reward, or wait a given amount of time to receive a reinforcing stimulus 
(Domjan, 2005; Panlilio & Goldberg, 2007).  
Ratio schedules require that a certain number of responses to pass before 
the subject receives the reinforcer (Domjan, 2005; Haney & Spealman, 2008; 
Panlilio & Goldberg, 2007; Spealman & Goldberg, 1978). In fixed-ratio (FR) 
scheduling, the subject receives the reinforcer after a certain number of 
responses. FR schedules typically produce high, steady rates of responding, with 
a brief pause in responding after the reinforcer is given (Domjan, 2005; Panlilio & 
Goldberg, 2007; Spealman & Goldberg, 1978). FR scheduling is often used to 
determine the reinforcing effects of long-lasting drugs that may result in an 
infrequent self-administration rate over time (Panlilio & Goldberg, 2007). 
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Typically, an FR 1 schedule (i.e., continuous reinforcement) is used for initial self-
administration training (Panlilio & Goldberg, 2007). When an animal has 
established consistent responding for reinforced drug delivery, the ratio can be 
increased sequentially (i.e., FR 2, FR 5, etc.) (Panlilio & Goldberg, 2007).  
 FR schedules of reinforcement are utilized in drug self-administration with 
laboratory animals, including cocaine, amphetamine, methamphetamine, 
caffeine, opiates, ethanol, and other addictive compounds (Balster, Kilbey, & 
Ellinwood, 1976; Deneau et al., 1969; Goldberg, 1973; Winger & Woods, 1973). 
When animals are given unlimited access to stimulants, such as cocaine, 
amphetamine, methamphetamine, methylphenidate, or caffeine, it produces 
increased periods of alternating consumption and abstinence (Deneau et al., 
1969; Johanson, Balster, & Bonese, 1976; Pickens & Harris, 1968; Yokel & 
Pickens, 1973). This is similar to what is observed in the human condition, with 
periods of binging and abstinence (Kramer, Vitezslav, & Littlefield, 1967). When 
given a reinforcement schedule that allows limited drug access, stimulant self-
administration produces smaller binges at the beginning of the session, and 
consistent drug intake throughout the remainder of the session (Gardner, 2000). 
Reinstatement and Relapse 
Reinstatement of a drug is used to model drug relapse after a period of 
abstinence (Bossert, Marchant, Calu, & Shaham, 2013; Sanchis-Segura & 
Spanagel, 2006). After multiple extinction sessions, the subject is then either re-
exposed to the original or different reinforcing drug, presented with drug-
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associated cues, or given foot shock stress within the self-administration 
chamber (Bossert et al., 2013; Sanchis-Segura & Spanagel, 2006). These types 
of treatments are meant to model triggers associated with relapse in humans 
(Bossert et al., 2013; Sanchis-Segura & Spanagel, 2006).  
Advantages and Disadvantages of Intravenous Self-Administration 
Given the various schedules and manipulations used in the drug self-
administration paradigm, it is clear that self-administration models many aspects 
of human addiction. When compared to other behavioral paradigms, self-
administration represents the highest point-to-point correspondence with 
addictive behaviors observed in the natural environment (Panlilio & Goldberg, 
2002). Therefore, self-administration procedures maintain a very high level of 
face validity, reliability, and species generality (Haney & Spealman, 2008). In 
regards to predictive validity, drug self-administration in animals predicts the 
abuse potential of new compounds in humans (Balster, 1991; Lile & Nader, 
2003). Self-administration procedures are often conducted via nose-poke holes 
or levers (Gardner, 2000). One advantage to using nose-pokes is that they are 
an innate behavior for rodents, whereas lever pressing is a learned behavior that 
can be time consuming. 
A limitation for the drug self-administration paradigm is expense in both 
time and other resources (Panlilio & Goldberg, 2002). Due to its complexity, the 
self-administration procedure may, in some cases, be less productive than 
simpler behavioral paradigms when screening for novel drugs or relating 
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addiction-like behaviors to neural circuitry (Panlilio & Goldberg, 2002). An 
additional limitation of intravenous self-administration is unique to ontogeny. 
Specifically, adolescent rats can quickly outgrow the implanted cannulas 
because of the normal growth that occurs during this developmental period. More 
importantly, because of the recovery time required after surgery, it is difficult to 
complete intravenous self-administration procedures during the short time span 
of adolescence. One way to avoid these problems is to change the route of drug 
administration.  
Oral Self-Administration 
Oral self-administration can be established in many different animals with 
a number of abused drugs (e.g., alcohol, opiates, and psychostimulants) 
(Meisch, 2001). Following a response (i.e., nose-poke or lever press), rats are 
presented with a spigot, to which they can lick a drug solution (Gardner, 2000). 
An automated device then measures individual licks taken by the rat (Gardner, 
2000). Another form of oral self-administration that does not make use of operant 
reinforcement procedures involves giving rats free access to two water bottles for 
a specified period of time, one containing vehicle and the other containing a 
solution of the drug of interest (Collins, Pogun, Nesil, & Kanit, 2012). The water 
bottles are then weighed and the preferred solution is determined (Collins et al., 
2012).   
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Advantages and Disadvantages of Oral Self-Administration 
The main advantage of the oral route of self-administration is that surgery 
is not necessary and there is no need for catheters, which avoids infection, 
obstruction, and incorrect placement (Macenski & Meisch, 1994). Additionally, 
the surgical procedures limit the amount of time an animal can be used in a given 
experiment (Macenski & Meisch, 1994).  
The main disadvantages of the oral route of self-administration include the 
lack of drug absorption resulting from chemical polarity, as well as the 
degradation of drugs via digestive enzymes and alternating pH levels (Turner, 
Brabb, Pekow, & Vasbinder, 2011). Other limitations include first pass effects by 
the liver, delayed time for drugs to reach the CNS and produce behavioral 
effects, the aversive taste of many drugs, and the small amounts of drug volume 
consumed per drinking episode (Macenski & Meisch, 1994; Meisch, 2001; Turner 
et al., 2011). Regardless of the possible limitations, laboratory animals have 
learned to orally self-administer using alcohol, cocaine, amphetamine, 
methamphetamine, and other psychoactive drugs (Meisch, 2001; Shabani et al., 
2013). 
  
51 
CHAPTER EIGHT 
THESIS PROPOSAL AND HYPOTHESES 
 
 
Adolescence is a vulnerable period in development, especially in regards 
to pharmacologically-induced changes in neurochemistry and resulting behavior 
(Stanis & Andersen, 2014). Cigarette smoking is most likely to begin during 
adolescence and can often serve as a gateway to other drugs of abuse 
(Lewinsohn et al., 1999). Adolescent methamphetamine use is also common, 
with about 1.6% of high school students having used methamphetamine in 2010 
(Panenka et al., 2013). Simultaneous nicotine and methamphetamine use is very 
prevalent, with an estimate that 97% of methamphetamine users also use 
nicotine (Brecht et al., 2004). Nicotine and methamphetamine have comparable 
effects on neural reward pathways, such as increasing DA in the nucleus 
accumbens (Dani & De Biasi, 2001; Nestler, 2005; Picciotto & Corrigall, 2002; 
Wise & Bozarth, 1984). When administered together, nicotine and 
methamphetamine display variable effects on reward-related behaviors (Hiranita 
et al., 2004; Neugebauer et al., 2010; Pipkin et al., 2014). The effects of nicotine 
and methamphetamine co-treatment have been seldom investigated, with little 
known about how these drugs interact in adolescent populations. 
Animal studies have shown a potential connection between nicotine and 
methamphetamine. For example, nicotine can be substituted for 
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methamphetamine in a discrimination procedure, which suggests that the two 
drugs possess similar properties (Gatch, Flores, & Forster, 2008). In mice, 
repeated nicotine treatment produces locomotor cross-sensitization when given a 
methamphetamine challenge (Kuribara, 1999). Thus, repeated cigarette smoking 
may increase the rewarding potential of initial methamphetamine use. 
Interestingly, the same study found that coadministration of methamphetamine 
and a high dose of nicotine reduced the induction of methamphetamine 
sensitization, suggesting that nicotine, in some cases, may contain protective 
properties against methamphetamine abuse potential (Kuribara, 1999). 
 In contrast to findings of nicotine and methamphetamine cross-
sensitization, prior nicotine exposure does not have an effect on 
methamphetamine CPP, extinction, or reinstatement, indicating that nicotine may 
not be responsible for an enhancement of the rewarding effects of 
methamphetamine (Berry et al., 2012). Although CPP and self-administration can 
both model the rewarding effects of certain drugs, it is evident that 
neuropharmacological mechanisms underlying the paradigms are dissociable 
(Bardo & Bevins, 2000). Thus, in rats previously trained to self-administer 
methamphetamine, nicotine exposure produces methamphetamine reinstatement 
(Neugebauer et al., 2010), suggesting that nicotine exposure during a withdrawal 
period may facilitate the onset of methamphetamine relapse. Methamphetamine 
pretreatment increases nicotine self-administration (Rauhut, Neugebauer, 
Dwoskin, & Bardo, 2003), further connecting the rewarding properties of the two 
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psychostimulants. Prenatal nicotine exposure produces heightened 
methamphetamine infusions in adulthood, which is congruent with the notion that 
early developmental nicotine exposure can enhance methamphetamine reward 
later in life (Lacy, Morgan, & Harrod, 2014). Thus, preclinical evidence suggests 
that nicotine exposure can augment the rewarding and abuse potential of 
methamphetamine in certain experimental conditions (e.g., self-administration, 
behavioral-sensitization); however, this effect is not observed in others (e.g., 
CPP). 
As for adolescent nicotine exposure on methamphetamine self-
administration in early adulthood, a low dose of nicotine treatment beginning in 
adolescence through adulthood augmented methamphetamine infusions (Pipkin 
et al., 2014), suggesting that a moderate amount of smoking during adolescence 
through adulthood may enhance the reinforcing effects of methamphetamine. In 
addition, nicotine-pretreated adolescent rats received more methamphetamine 
intake in adulthood than saline-pretreated adolescent rats (Pipkin et al., 2014). 
Thus, adolescent cigarette smoking may increase the reward potential of 
methamphetamine in adulthood. 
In regards to methamphetamine withdrawal and relapse, adolescent 
nicotine exposure had no effect on methamphetamine extinction or reinstatement 
in adult rats (Pipkin et al., 2014). Therefore, adolescent cigarette smoking may 
not alter methamphetamine seeking and relapse in adulthood. Alternatively, a 
high dose of nicotine exposure during a 5-day methamphetamine withdrawal 
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period attenuated lever-responding in adult rats following a single 
methamphetamine priming injection (Hiranita et al., 2004; 2006), suggesting that 
nicotine exposure, under certain experimental conditions, can reduce 
methamphetamine seeking and risk associated with relapse. It is evident that the 
effects of adolescent or adult nicotine exposure on methamphetamine self-
administration, extinction, and reinstatement vary widely based on various 
experimental procedures and design (i.e., age of animal, dose, and behavioral 
paradigm). 
Lastly, there is clear pre-clinical evidence suggesting sex differences exist 
in regards to the reinforcing properties of nicotine or methamphetamine. During 
nicotine self-administration, female rats maintain a higher motivation to obtain 
nicotine than male rats, while no sex differences are observed during nicotine-
induced reinstatement (Donny et al., 2000; Feltenstein, Ghee, & See, 2012). 
Similar to the sex differences observed within nicotine self-administration, female 
rats are more susceptible to the reinforcing properties of methamphetamine than 
male rats. Specifically, female rats acquire methamphetamine self-administration 
more readily than male rats (Kucerova, Vrskova, & Sulcova, 2009; Reichel, 
Chan, Ghee, & See, 2012; Roth & Carroll, 2004; Ruda-Kucerova et al., 2015). 
During methamphetamine reinstatement, female rats respond more for access to 
methamphetamine than male rats (Ruda-Kucerova et al., 2015). Given the 
distinct differences between male and female rats observed within nicotine or 
methamphetamine reinforcement procedures, it is possible that sex may alter 
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adolescent nicotine exposure-induced changes on methamphetamine self-
administration, extinction, and reinstatement. 
The aim of the present investigation was to gain a further understanding 
about the effects of nicotine exposure on the reinforcing properties of 
methamphetamine during adolescence. To this end, we assessed 
methamphetamine acquisition, extinction, and reinstatement in adolescent male 
and female rats. Employing an oral self-administration procedure allowed us to 
test rats during this pivotal developmental period. Moreover, this method 
shortened training time and omitted surgical procedures, which allowed for the 
testing of a large number of subjects and a more complicated research design. 
The PD 25 to PD 65 age range was selected to approximate adolescence 
(Spear, 2000), which the oral self-administration paradigm was used to model 
human addiction. A total of seven treatment groups were used in order to 
precisely determine whether nicotine exposure enhances or diminishes the 
reinforcing effects of methamphetamine during the adolescent period. On PD 25, 
adolescent male and female rats were injected with saline or nicotine (0.16 or 
0.64 mg/kg, sc) once a day for 10 days until PD 34. Subsequently, half of the 
nicotine-pretreated rats continued to receive nicotine at the same doses, while 
the other half received saline for the remainder of the experiment. In addition, 
one third of the saline pretreated rats continued to receive saline, while two thirds 
received nicotine (0.16 or 0.64 mg/kg) for the remainder of the experiment (see 
Figure 1). On PD 35, rats underwent training to nose poke for a 10% sucrose 
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solution. After reaching sucrose-training criteria, methamphetamine acquisition 
occurred across seven different 2 h sessions. When criteria were met, rats began 
extinction training, where nose poke responses were not reinforced. Once 
extinction criteria were met, all rats were given a priming injection of 
methamphetamine (1.0 mg/kg) in order to induce reinstatement of 
methamphetamine responding. 
 
Figure 1. Project design and timeline. 
 
Overall, we had two primary hypotheses about how nicotine and sex 
would affect oral methamphetamine self-administration: 
First, we predicted that nicotine exposure would alter consumption and 
responding for methamphetamine. We hypothesized that exposure to a low dose 
of nicotine (0.16 mg/kg) would enhance consumption and responding for 
methamphetamine. In contrast, we hypothesized that exposure to a high dose of 
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nicotine (0.64 mg/kg) would attenuate consumption and responding for 
methamphetamine. These hypotheses were founded in past research showing 
that exposure to low doses of nicotine potentiates the rewarding properties of 
methamphetamine or cocaine (McQuown et al., 2007; Pipkin et al., 2014), 
whereas exposure to higher doses of nicotine attenuates methamphetamine self-
administration and reinstatement (Hiranita et al., 2004; 2006; Neugebauer et al., 
2010). 
Second, we predicted that sex would also alter consumption and 
responding for methamphetamine. We hypothesized that female rats would have 
enhanced consumption and responding for methamphetamine. These 
hypotheses were founded in past research showing that female rats acquire 
methamphetamine self-administration more readily (Kucerova, Vrskova, & 
Sulcova, 2009), as well as respond more for access to methamphetamine during 
reinstatement than male rats (Ruda-Kucerova et al., 2015). Moreover, we 
hypothesized that female rats would show larger changes in responding for 
methamphetamine and consumption at both doses of nicotine. 
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Table 1. Hypothesized Main Effects and Interactions for Nicotine (0.16 or 0.64 
mg/kg) Treatment and Sex (Male or Female) Across Methamphetamine Self-
Administration, Extinction, and Reinstatement. 
 
  
Sex
Main Effect
Pre- or Post-Treatment
Main Effect
Sex × Pre- or Post-Treatment
Interaction
 Pre- × Post-Treatment
Interaction
Sex × Pre- and Post-Treatment
Interaction
Sex
Main Effect
Pre- or Post-Treatment
Main Effect
Sex × Pre- or Post-Treatment
Interaction
 Pre- × Post-Treatment
Interaction
Sex × Pre- and Post-Treatment
Interaction
Low Dose (0.16 mg/kg)
Female > Male
Nicotine (0.16 mg/kg) > Saline
Female (0.16 mg/kg) > Female Saline
Female (0.16 mg/kg) > Male (0.16 mg/kg) or Saline
0.16-0.16 > SAL-SAL, 0.16-SAL, SAL-0.16
SAL-SAL > 0.64-0.64, 0.64-SAL, SAL-0.64
Male (0.64-0.64) < Male (SAL–SAL; 0.64–SAL; SAL–0.64)
Male (0.64-0.64) < Female (SAL–SAL; 0.64–SAL; SAL–0.64; 0.64-0.64)
Female (0.16-0.16) > Female (SAL–SAL; 0.16–SAL; SAL–0.16)
Female (0.16-0.16) > Male (SAL–SAL; 0.16–SAL; SAL–0.16;0.16-0.16)
High Dose (0.64 mg/kg)
Female > Male
Saline > Nicotine (0.64 mg/kg)
Male (0.64 mg/kg) < Male Saline
Male (0.64 mg/kg) < Female (0.64 mg/kg) or Saline
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CHAPTER NINE 
MATERIALS AND METHODS  
Subjects 
Subjects were 164 young male and female rats (n = 911) of Sprague-
Dawley descent (Charles River, Hollister, CA). Four subjects were found to be 
statistical outliers and removed from data analyses. Rats were housed with the 
dam until being weaned on PD 23, after which they were housed with same-sex 
littermates in large maternity cages. Food and water were provided ad-libitum, 
except as noted below. The colony room was maintained at 2123 C and kept 
under a 12 L:12 D cycle. Rats were tested in a quiet, separate room during the 
light phase of the cycle. Subjects were cared for according to the “Guide for the 
Care and Use of Mammals in Neuroscience and Behavioral Research” (National 
Research Council, 2010) under a research protocol approved by the Institutional 
Animal Care and Use Committee of CSUSB. 
Apparatus 
Behavioral testing occurred in standard operant chambers (Coulbourn 
Instruments, Whitehall, PA). Each chamber contained two nose poke 
operandums (2 cm from the floor), an optical lickometer, a house light, a stimulus 
light, and a sound cue (500 Hz, 10 dB above background). The two nose poke 
operandums were positioned on the front wall of the chamber, with the optical 
lickometer positioned between the two nose poke operandums. The stimulus 
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light and sound cue were located directly above the active nose poke hole. The 
location of the active nose poke hole was counterbalanced across all self-
administration chambers on either the left or right side of the optical lickometer. 
Nose pokes in the active nose poke hole resulted in rats receiving access to a 
reinforcer (e.g., sucrose or methamphetamine) for 30 s. Nose pokes in the 
inactive nose poke hole resulted in no scheduled consequences. The house light 
was located on the rear wall of the chamber and remained on while rats were 
inside the operant chambers, except during timeout periods, wherein the house 
light was turned off for 20 s. Each chamber was housed in a soundproof isolation 
cubicle and controlled by an IBM compatible computer interfaced with a data 
collection program (Graphic State, Coulbourn Instruments).  
Drugs 
(−)-Nicotine hydrogen tartrate and (±)-methamphetamine hydrochloride 
(Sigma-Aldrich, St. Louis, MO) was dissolved in saline. Nicotine injections were 
administered subcutaneously (SC), whereas methamphetamine injections were 
administered intraperitoneally (IP). Methamphetamine and sucrose were 
dissolved in distilled water for drinking solutions. 
Procedures 
In Vivo Drug Treatment 
Starting on PD 25, rats were weighed and then injected with nicotine (0.16 
or 0.64 mg/kg) or saline for 10 consecutive days until PD 34 (see Figure 2). This 
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injection period (PD 25−PD 34) is developmentally comparable to early 
adolescence in humans (Anderson, 2003). On PD 35, rats in the 0.16 and 0.64 
mg/kg pretreatment groups were evenly divided and assigned to a group that 
either continued to receive the same nicotine dose they received as adolescents 
or saline. Rats that had received saline as adolescents were divided into three 
equal groups, where they received 0.16 or 0.64 mg/kg nicotine or continued to 
receive saline injections. Drug treatments starting on PD 35 continued until the 
end of the experiment. In total, there were 7 drug groups: SAL–SAL, 0.16–0.16, 
0.16–SAL, SAL–0.16, 0.64–0.64, 0.64–SAL, SAL0.64. 
Nose Poke Training 
Starting on PD 33, rats were pre-exposed to a 10% sucrose solution for 32 
h in their home cage. On PD 35, rats were placed in a self-administration 
chamber and allowed to nose poke for access to a 10% sucrose (w/v) solution on 
an FR1 schedule for 60 min each day until a criterion of ≥ 10 presentations for 2 
consecutive days was met. Following each session, rats were treated with 
nicotine (0.16 or 0.64 mg/kg) or saline in their home cage. Nose poke responses 
in the active hole resulted in the simultaneous presentation of a stimulus light, 
sound cue (500 Hz, 10 dB above background), and a 30 s presentation of a liquid 
dropper (i.e., reinforcement period). After each liquid dropper presentation, the 
active nose poke hole became inactive for 20 s, which was indicated by the 
absence of the house light (i.e., timeout period). On training days, water 
availability was restricted for 16 hr/day to accelerate acquisition of operant 
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responding. Following nose poke training, rats were food restricted to 90% of 
their free-feeding weight for the remainder of the experiment, while water was 
made available ad-libitum. Rats that failed to meet training criterion were 
excluded from the study. 
Methamphetamine Self-Administration 
Once the sucrose-training criterion was met, methamphetamine fade-in 
and sucrose fade-out began across seven (2 h) sessions (adopted from Shabani 
et al., 2013; see Figure 2). Each nose poke response in the active hole resulted 
in the simultaneous presentation of a stimulus light, sound cue (500 Hz, 10 dB 
above background), and a 30 s presentation of a liquid dropper that delivered 
either a sucrose, methamphetamine, or sucrose and methamphetamine solution 
(i.e., reinforcement period). After each liquid dropper presentation, the active 
nose poke hole became inactive for 20 s, which was indicated by the absence of 
the house light (i.e., timeout period). During sessions 12 liquid solutions were 
presented on an FR1 schedule; during sessions 37 liquid solutions were 
presented on an FR2 schedule. The criterion for sessions 16 was ≥ 10 
presentations for each 2 hr session. Sessions 1 and 3 required a criterion of ≥ 10 
presentations for 2 consecutive days. Rats were exposed to session 7 for three 
consecutive days. If rats did not meet criteria for a particular session, then rats 
remained on that session at least 4 days, after which they were advanced to the 
next session. 
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Session 1 served as a baseline, in which a 10% sucrose solution was 
presented alone. On session 2, methamphetamine fade-in and sucrose fade-out 
began. Specifically, a low dose of methamphetamine (20 mg/l) was introduced 
into an 8.5% sucrose solution. On sessions 36, a high dose of 
methamphetamine (40 mg/l) was introduced into the sucrose solutions (i.e., 6.5% 
for session 3, 4.5% for session 4, 2.5% for session 5, and 0.5% for session 6). 
On session 7, no sucrose was present in the methamphetamine (40 mg/l) liquid 
solution (see Figure 2). 
 
Figure 2. Methamphetamine acquisition 
Extinction Training 
Extinction training began following methamphetamine (40 mg/l) acquisition 
(see Figure 1). During extinction, rats underwent 2 h training sessions, in which 
nose poke behavior resulted in no scheduled consequences, but responses were 
recorded. Rats remained in extinction for 7 consecutive days or until active nose 
poke responses were < 10% of the last day of FR2 methamphetamine (40 mg/l) 
acquisition for two consecutive days. 
Drug Prime Reinstatement 
Once extinction criteria were met, all rats were given a priming injection of 
methamphetamine (1.0 mg/kg, IP) 5 min before being placed in the self-
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administration chambers (see Figure 1). Reinstatement sessions lasted 2 h, 
during which nose pokes resulted in no consequences. 
Data Analysis 
Data for acquisition, extinction, and reinstatement sessions were collected 
using Graphic State program software (Coulbourn Instruments). Total active and 
inactive nose pokes, active and inactive nose pokes during the timeout period, 
active nose pokes during the reinforcement period, and amount of volume 
consumed (i.e., sucrose and/or methamphetamine) were recorded and 
calculated for all acquisition and self-administration sessions. Total active and 
inactive nose pokes were recorded and calculated for all extinction and 
reinstatement sessions. Data from rats exposed to a low dose of nicotine (0.16 
mg/kg) or a high dose of nicotine (0.64 mg/kg) were analyzed separately. Thus, 
all data from methamphetamine self-administration and reinstatement sessions 
were analyzed by 2×2×2 ANOVAs (sex × pre-treatment × post-treatment). 
Acquisition training data (sucrose training – session 6) were analyzed with mixed 
between-within ANOVAs, with session as the within subjects variable and sex, 
pre-treatment, and post-treatment as the between subjects variables (session × 
sex × pre-treatment × post-treatment). Extinction data were analyzed with mixed 
between-within ANOVAs, with day as the within subjects variable and sex, pre-
treatment, and post-treatment as the between subjects variables (day × sex × 
pre-treatment × post-treatment). If needed, data were further analyzed with one-
way ANOVAs. In addition, body weight data were analyzed with mixed between-
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within ANOVAs, with day as the within subjects variable and sex, pre-treatment, 
and post-treatment as the between subjects variables (day × sex × pre-treatment 
× post-treatment). If the assumption of sphericity was violated, then the 
Greenhouse-Geisser correction was used. Post hoc comparisons were made 
with Tukey tests, p < .05. 
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CHAPTER TEN 
RESULTS 
Effects of Nicotine (0.16 mg/kg) Exposure on Oral Methamphetamine Self-
Administration, Extinction, and Reinstatement 
Effect of Nicotine (0.16 mg/kg) Exposure on Bodyweight 
Adolescent nicotine (0.16 mg/kg) exposure across the pre- (PD 25−PD 34) 
and post-treatment (PD 35−54) phases did not alter bodyweights of either male 
or female rats. Bodyweights of all rats progressively increased across the pre- 
(PD 25−PD 34) and post-treatment (PD 35−54) periods [day main effect, 
F(1.99,1.63.96) = 696.69, p > .001] (see Figure 3). Male rats (M = 175.80, SEM = 
2.70) weighed more than female rats (M = 143.75, SEM = 2.81) across the pre- 
and post-treatment periods [sex main effect, F(1,75) = 67.64, p > .001] (see 
Figure 3). 
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Figure 3. Mean body weight (± SEM) of male and female rats exposed to saline 
(SAL) or nicotine (0.16 mg/kg) during the pre- (PD 25–34) or post-treatment (PD 
35–~60) phases.  
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Acquisition of Methamphetamine Self-Administration 
Oral methamphetamine self-administration was acquired over six training 
sessions, in which sucrose was phased out and methamphetamine was 
introduced. On session 7, rats responded for methamphetamine alone. In 
general, neither pre- nor post-treatment with nicotine (0.16 mg/kg) altered 
consumption or responding for methamphetamine (see Figure 4). However, rats 
exposed to saline during the pre-treatment period had more inactive nose pokes 
within the timeout period than rats exposed to nicotine (0.16 mg/kg) during the 
pre-treatment period [pre-treatment main effect, F(1,75) = 7.02, p < .01] (see 
Figure 5D). 
Sex did not alter consumption or responding for methamphetamine during 
the first six sessions (see Figure 4); however, female rats had more active nose 
pokes during the timeout period than male rats across methamphetamine 
acquisition training [sex main effect, F(1,75) = 5.12, p < .05] (see Figure 5B & 
6A). In addition, female rats had more total inactive nose pokes than male rats 
across methamphetamine acquisition training [sex main effect, F(1,75) = 12.70, 
p < .001] (see Figures 5C & 6B). Lastly, female rats had more inactive nose 
pokes during the timeout period than male rats [sex main effect, F(1,75) = 7.95, 
p < .01] (see Figures 5D & 6C). 
None of the remaining dependent measures (i.e., total active nose pokes) 
were altered by nicotine (0.16 mg/kg) or sex (see Figure 5).  
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Figure 4. A) Mean sucrose and methamphetamine consumption; and B) mean 
number of active nose pokes (reinforcement) (± SEM) for male and female rats 
on the last day of behavioral responding across methamphetamine acquisition 
training sessions (sucrose training–session 6). Rats were exposed to saline 
(SAL) or nicotine (0.16 mg/kg) during the pre- (PD 25–34) or post-treatment (PD 
35–~60) periods.  
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Figure 5. A) Mean number of active nose pokes (total); B) mean number of active 
nose pokes (timeout); C) mean number of inactive nose pokes (total); and D) 
mean number of inactive nose pokes (timeout) (± SEM) for male and female rats 
on the last day of behavioral responding across methamphetamine acquisition 
training sessions (sucrose training–session 6). Rats were exposed to saline 
(SAL) or nicotine (0.16 mg/kg) during the pre- (PD 25–34) or post-treatment (PD 
35–~60) periods.  
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Figure 6. A) Mean number of active nose pokes (timeout); B) mean number of 
inactive nose pokes (total); and C) mean number of inactive nose pokes 
(timeout) (± SEM) for male and female rats on the last day of behavioral 
responding across methamphetamine acquisition training sessions (sucrose 
training–session 6). * Indicates a significant difference from male rats (p < .05).  
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Post-treatment with nicotine (0.16 mg/kg) altered consumption and 
responding for methamphetamine on session 7. Specifically, rats exposed to 
saline during the post-treatment period had more active nose pokes within the 
reinforcement period, and greater methamphetamine consumption (40 mg/l 
methamphetamine solution), than rats exposed to a low dose of nicotine (0.16 
mg/kg) during the post-treatment period [post-treatment main effect, 
F(1,75) = 4.09, p > .05; F(1,75) = 5.22, p > .05, respectively] (see Figures 7A & 
7B). Pre-treatment with nicotine (0.16 mg/kg) did not alter consumption or 
responding for methamphetamine on session 7; however, rats exposed to saline 
during the pre-treatment period had more total inactive nose pokes compared to 
rats exposed to a low dose of nicotine (0.16 mg/kg) during the pre-treatment 
period [pre-treatment main effect, F(1,75) = 5.17, p > .05] (see Figures 7E). 
Sex also altered responding for methamphetamine on session 7, because 
female rats had more total active nose pokes and active nose pokes within the 
reinforcement period than male rats [sex main effect, F(1,75) = 4.53, p < .05; 
F(1,75) = 5.56, p < .05, respectively] (see Figures 7B, 7C, 8A, & 8B). Female rats 
also had more active nose pokes within the timeout period and more total 
inactive nose pokes than male rats [sex main effect, F(1,75) = 11.13, p < .01; 
F(1,75) = 4.98, p < .05, respectively] (see Figures 7D, 7E, 8C, & 8D).  
None of the remaining dependent measures (i.e., inactive nose pokes 
during the timeout period) were altered by nicotine (0.16 mg/kg) treatment or sex 
(see Figure 7).  
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Figure 7. A) Mean methamphetamine (40 mg/l) consumption; B) mean number of 
active nose pokes (reinforcement); C) mean number of active nose pokes (total); 
D) mean number of active nose pokes (timeout); E) mean number or inactive 
nose pokes (total); and F) mean number of inactive nose pokes (timeout) 
(± SEM) made by adolescent male and female rats during methamphetamine 
acquisition on session 7 (FR 2). Rats were exposed to saline (SAL) or nicotine 
(0.16 mg/kg) during the pre-treatment (PD 25–34) or post-treatment (PD 35–~60) 
phases.  
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Figure 8. A) Mean number of active nose pokes (reinforcement); B) mean 
number of active nose pokes (total); C) mean number of active nose pokes 
(timeout); and D) mean number of inactive nose pokes (total) (± SEM) made by 
male and female rats during methamphetamine (40 mg/l) acquisition on session 
7 (FR 2). * Indicates a significant difference from male rats (p < .05).  
0
50
100
150
*
Male Female
0
20
40
60
 
Sex
*
Male Female
0
5
10
15
 
Sex
*
0
10
20
30
*
A
C
B
D
A
c
tiv
e
 N
o
s
e
 P
o
k
e
s
  
  
  
  
  
(T
o
ta
l)
A
c
tiv
e
 N
o
s
e
 P
o
k
e
s
  
  
  
  
(T
im
e
o
u
t)
  
  
A
c
tiv
e
 N
o
s
e
 P
o
k
e
s
  
  
  
(R
e
in
fo
rc
e
m
e
n
t)
In
a
c
tiv
e
 N
o
s
e
 P
o
k
e
s
  
  
  
  
  
  
 (
T
o
ta
l)
75 
Extinction Training and Drug-Primed Reinstatement 
Active nose pokes decreased across the seven extinction days [active, 
F(4.04,326.99) = 8.69, p < .001] (see Figure 9A). In contrast, inactive nose pokes 
remained relatively constant across extinction days [inactive, F(6,486) = .741, 
p = .617] (see Figure 9B). 
Total active nose pokes were not altered by nicotine (0.16 mg/kg) pre- or 
post-treatment during extinction (see Figure 9A). Rats exposed to saline during 
the pre-treatment period had more total inactive nose pokes across extinction 
days than rats exposed to nicotine (0.16 mg/kg) during the pre-treatment period 
[pre-treatment main effect, F(1,74) = 8.42, p < .01] (see Figure 9B). 
Sex altered responding for methamphetamine during extinction. 
Specifically, female rats had more total active nose pokes across extinction days 
than male rats [sex main effect, F(1,74) = 8.42, p < .01] (see Figures 9A & 9C). 
Total inactive nose pokes did not differ by sex during extinction (see Figure 9B). 
Total active nose pokes were not altered by nicotine (0.16 mg/kg) pre- or 
post-treatment during reinstatement (see Figure 10A). Rats exposed to saline 
during the pre-treatment period had more total inactive nose pokes than rats 
exposed to a low dose of nicotine (0.16 mg/kg) during the pre-treatment period 
[pre-treatment main effect, F(1,75) = 4.43, p < .05] (see Figures 10B & 11). 
Lastly, sex did not alter total active and inactive nose pokes during 
reinstatement (see Figure 10). 
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Figure 9. A) Mean number of active nose pokes (total); B) mean number of 
inactive nose pokes (total); and C) mean number of active nose pokes (total) 
(± SEM) made by male and female rats during extinction training days 1 – 7. 
Rats were exposed to saline (SAL) or nicotine (0.16 mg/kg) during the pre-
treatment (PD 25–34) or post-treatment (PD 35–~60) phases. * Indicates a 
significant difference from male rats (p < .05).  
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Figure 10. A) Mean number of active nose pokes (total); and B) mean number of 
inactive nose pokes (total) (± SEM) made by male and female rats during the 
reinstatement period. Rats were exposed to saline (SAL) or nicotine (0.16 mg/kg) 
during the pre-treatment (PD 25–34) or post-treatment (PD 35–~60) phases.  
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Figure 11. Mean number of inactive nose pokes (total) (± SEM) made by 
adolescent rats during methamphetamine reinstatement. Rats were exposed to 
saline (SAL) or nicotine (0.16 mg/kg) during the pre-treatment phase. * Indicates 
a significant different from saline treated rats (p < .05). 
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Effects of Nicotine (0.64 mg/kg) Exposure on Oral Methamphetamine Self-
Administration, Extinction, and Reinstatement 
Effect of Nicotine (0.64 mg/kg) Exposure on Bodyweight 
Adolescent nicotine (0.64 mg/kg) exposure across the pre- (PD 25−PD 34) 
and post-treatment (PD 35−54) phases did not alter bodyweights of either male 
or female rats. Bodyweights of all rats progressively increased across the pre- 
(PD 25−PD 34) and post-treatment (PD 35−54) periods [day main effect, 
F(1.83,146.32) = 542.52, p > .001] (see Figure 12). Male rats (M = 157.57, SEM 
= 2.34) weighed more than female rats (M = 129.47, SEM = 2.36) across the pre- 
and post-treatment periods [sex main effect, F(1,73) = 71.64, p > .001] (see 
Figure 12). 
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Figure 12. Mean body weight (± SEM) of male and female rats exposed to saline 
(SAL) or nicotine (0.64 mg/kg) across the pre- (PD 25–34) or post-treatment (PD 
35–~60) phases. 
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Acquisition of Methamphetamine Self-Administration 
Oral methamphetamine self-administration was acquired over six training 
sessions, in which sucrose was phased out and methamphetamine was 
introduced. On session 7, rats responded for methamphetamine alone. Neither 
pre- nor post-treatment with nicotine (0.64 mg/kg) altered consumption or 
responding for methamphetamine (see Figure 13). Male rats (M = 7.92, SEM  = 
.36) consumed more sucrose and methamphetamine than female rats (M = 6.17, 
SEM  = .37) [sex main effect, F(1,73) = 11.46, p < .01] (see Figure 13A). 
None of the remaining dependent measures (i.e., total active and inactive 
nose pokes, active and inactive nose pokes during the timeout period) were 
altered by nicotine (0.64 mg/kg) or sex (see Figure 14). 
  
82 
 
Figure 13. A) Mean sucrose and methamphetamine consumption; and B) mean 
number of active nose pokes (reinforcement) (± SEM) made by male and female 
rats exposed to saline (SAL) or nicotine (0.64 mg/kg) across the pre- (PD 25–34) 
or post-treatment (PD 35–~60) phases during methamphetamine acquisition 
training sessions (sucrose training–session 6). 
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Figure 14. A) Mean number of active nose pokes (total); B) mean number of 
active nose pokes (timeout); C) mean number of inactive nose pokes (total); and 
D) mean number of inactive nose pokes (timeout) (± SEM) made by male and 
female rats exposed to saline (SAL) or nicotine (0.64 mg/kg) across the pre- (PD 
25–34) or post-treatment (PD 35–~60) phases during methamphetamine 
acquisition training sessions (sucrose training–session 6).  
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Neither pre- nor post-treatment with nicotine (0.64 mg/kg) altered 
consumption or responding for methamphetamine on session 7 (see Figure 15). 
Sex altered responding for methamphetamine on session 7 because 
female rats had more total active nose pokes and more active nose pokes within 
the reinforcement period than male rats [sex main effect, F(1,73) = 3.97, p < .05; 
F(1,73) = 6.36, p < .05, respectively] (see Figures 15B, 15C, 16A & 16B). Female 
rats also had more total inactive nose pokes and more inactive nose pokes within 
the timeout period than male rats [sex main effect, F(1,73) = 4.08, p < .05; 
F(1,73) = 4.57, p < .05, respectively] (see Figures 15E, 15F, 16C & 16D).  
None of the remaining dependent measures (i.e., active nose pokes 
during the timeout period) were altered by nicotine (0.64 mg/kg) or sex (see 
Figure 15).  
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Figure 15. A) Mean methamphetamine (40 mg/l) consumption; B) mean active 
nose pokes (reinforcement); C) mean active nose pokes (total); D) mean active 
nose pokes (timeout); E) mean inactive nose pokes (total); and F) mean inactive 
nose pokes (timeout) (± SEM) made by adolescent male and female rats during 
methamphetamine acquisition on session 7 (FR 2). Rats were exposed to saline 
(SAL) or nicotine (0.64 mg/kg) during the pre-treatment (PD 25–34) or post-
treatment (PD 35–~60) phases.  
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Figure 16. A) Mean number of active nose pokes (reinforcement); B) mean active 
nose pokes (total); C) mean number of inactive nose pokes (total); and D) mean 
number of inactive nose pokes (timeout) (± SEM) made by adolescent male and 
female rats during methamphetamine (40 mg/l) acquisition session 7 (FR 2). * 
Indicates a significant difference from male rats (p < .05).  
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Extinction Training and Drug-Primed Reinstatement 
Active nose pokes decreased across extinction days [active, 
F(2.91,232.4) = 6.73, p < .001] (see Figure 17A). This decrease in active lever 
presses was not altered by sex or nicotine (0.64 mg/kg) exposure. Inactive nose 
pokes did not significantly change across extinction days [inactive, 
F(3.98,318.00) = 1.26, p = .274] (see Figure 17B). Inactive lever presses were 
not altered by sex or nicotine (0.64 mg/kg) exposure. 
Neither nicotine (0.64 mg/kg) exposure nor sex altered total active or 
inactive nose pokes during extinction training (see Figure 17A & 17B). Similarly, 
neither nicotine (0.64 mg/kg) exposure nor sex altered total active or inactive 
nose pokes during methamphetamine-primed reinstatement (see Figure 18A & 
18B). 
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Figure 17. A) Mean number of active nose pokes (total); and B) mean number of 
inactive nose pokes (total) (± SEM) made by adolescent male and female rats 
during methamphetamine extinction. Rats were exposed to saline (SAL) or 
nicotine (0.64 mg/kg) during the pre-treatment (PD 25–34) or post-treatment (PD 
35–~60) phases. 
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Figure 18. A) Mean number of active nose pokes (total); and B) mean number of 
inactive nose pokes (total) (± SEM) made by rats during reinstatement. Rats 
were exposed to saline (SAL) or nicotine (0.64 mg/kg) during the pre-treatment 
(PD 25–34) or post-treatment (PD 35–~60) phases. 
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 CHAPTER ELEVEN 
DISCUSSION 
Introduction 
Cigarette smoking is most likely to begin during the adolescent period, and 
often functions as a gateway to other drugs of abuse, such as methamphetamine 
(Lewinsohn et al., 1999). Methamphetamine use during adolescence is 
particularly troublesome given the severe psychological and physiological 
consequences of methamphetamine abuse (Russell et al., 2008; Vearrier et al., 
2012). Given that adolescence is a vulnerable period in development, in which 
cigarette smoking can lead to the onset of methamphetamine use and addiction, 
it is imperative to investigate the neurobiological relationship between these 
highly addictive drugs during the adolescent period (Yuan, Cross, Loughlin, & 
Leslie, 2015). Therefore, the aim of the present thesis was to determine the role 
of adolescent nicotine exposure on the reinforcing properties of 
methamphetamine, as well as drug seeking behavior, through the use of an oral 
methamphetamine self-administration procedure. 
We had two primary hypotheses. First, we hypothesized that nicotine 
exposure would alter methamphetamine self-administration and 
methamphetamine drug seeking behavior. Specifically, we predicted that 
exposure to a low dose of nicotine (0.16 mg/kg) would enhance the reinforcing 
effects of methamphetamine (i.e., increased consumption and more active nose 
pokes) compared to rats exposed to saline. Conversely, we predicted that 
91 
exposure to a high dose of nicotine (0.64 mg/kg) would attenuate the reinforcing 
effects of methamphetamine (i.e., decreased consumption and a reduced 
number of active nose pokes) compared to rats exposed to saline. These 
hypotheses were founded in past research showing that exposure to low doses 
of nicotine potentiates the rewarding properties of methamphetamine and 
cocaine (McQuown et al., 2007; Pipkin et al., 2014), whereas exposure to higher 
doses of nicotine attenuates methamphetamine self-administration and 
reinstatement (Hiranita et al., 2004; 2006; Neugebauer et al., 2010).  
Second, we hypothesized that sex would alter methamphetamine self-
administration and methamphetamine drug seeking behavior. Specifically, we 
predicted that female rats would display behavior indicating an enhancement of 
the reinforcing effects of methamphetamine (i.e., increased consumption and 
more active nose pokes) compared to male rats. These hypotheses were 
founded in past research showing that female rats acquire methamphetamine 
self-administration more readily (Kucerova, Vrskova, & Sulcova, 2009), as well 
as respond more for access to methamphetamine during reinstatement, than 
male rats (Ruda-Kucerova et al., 2015). 
During methamphetamine acquisition training sessions (i.e., sucrose 
training – session 6), nicotine (0.16 or 0.64 mg/kg) exposure did not alter 
consumption or responding for methamphetamine; however, rats exposed to 
saline had more inactive nose pokes within the timeout period than rats exposed 
to a low dose of nicotine (0.16 mg/kg). 
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During methamphetamine self-administration (i.e., session 7), nicotine 
(0.16 mg/kg) exposure altered consumption and responding for 
methamphetamine. In contrast to our hypotheses, rats exposed to saline during 
the post-treatment period had more active nose pokes during the reinforcement 
period and more methamphetamine consumption than rats exposed to a low 
dose of nicotine (0.16 mg/kg) during the post-treatment period. Nicotine (0.16 
mg/kg) exposure during the pre-treatment period did not alter consumption or 
responding for methamphetamine. Rats exposed to saline during the pre-
treatment period had more total inactive nose pokes compared to rats exposed to 
a low dose of nicotine (0.16 mg/kg) during the pre-treatment period. Neither pre- 
nor post-treatment with a high dose of nicotine (0.64 mg/kg) altered consumption 
or responding for methamphetamine during self-administration. 
During the extinction and reinstatement periods, nicotine (0.16 or 0.64 
mg/kg) exposure did not alter consumption or responding for methamphetamine; 
however, rats exposed to saline during the pre-treatment period had more total 
inactive nose pokes across extinction days than rats exposed to nicotine (0.16 
mg/kg) during the pre-treatment period. During the reinstatement period, rats 
exposed to saline during the pre-treatment period had more total inactive nose 
pokes than rats exposed to a low dose of nicotine (0.16 mg/kg) during the pre-
treatment period. 
The present results also demonstrated that oral methamphetamine self-
administration differed by sex. Consistent with our hypotheses, female rats had 
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augmented total active nose pokes and a greater number of active nose pokes 
within the reinforcement period compared to male rats. Conversely, male rats 
showed augmented sucrose and methamphetamine solution consumption across 
methamphetamine acquisition training sessions (i.e., sucrose training – session 
6). Female rats had augmented total inactive nose pokes, as well as more active 
and inactive nose pokes, within the timeout period compared to male rats. During 
extinction, female rats had an augmented number of total inactive nose pokes 
compared to male rats; however, no sex differences were observed during 
methamphetamine reinstatement. 
From a methodological perspective, the present thesis highlights that oral 
methamphetamine self-administration can be achieved in adolescent rats. 
Specifically, all groups, regardless of sex or drug treatment, exhibited 
consumption and operant responding for methamphetamine through the oral 
route of administration. To our knowledge, very few studies have utilized oral 
methamphetamine self-administration in mice (Shabani et al., 2013), with no 
published research demonstrating this effect in rats. As a genetic animal model 
of methamphetamine addiction, Shabani et al. (2013) utilized selectively bred 
mice to consume methamphetamine at either high or low rates. These 
researchers found that high methamphetamine-drinking mice have augmented 
intake, but a similar number of active lever presses when compared to low 
methamphetamine-drinking mice in the oral self-administration procedure. In 
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addition, they found comparable results utilizing an intracerebroventricular route 
of methamphetamine self-administration. 
The present thesis and Shabani et al. (2013) utilized similar acquisition 
training, in which sucrose faded-out and methamphetamine faded-in across 
seven different sessions. This type of acquisition is frequently used in oral 
ethanol self-administration studies (Ford et al., 2009). One difference between 
acquisition in the present thesis and Shabani et al. (2013) includes the use of 
sucrose or saccharin, respectively. In addition, mice in Shabani et al. (2013) 
underwent five, 1 hr operant trials for every change in solution or fixed ratio 
scheduling, resulting in a total of 35 operant trials. In the present thesis, rats 
underwent 2 hr operant trials, in which advancement to the next session was 
dependent on meeting specific criteria (e.g., 10 or more presentations). Due to 
the short adolescent period in rats (~30 days), it was necessary to utilize the 
more abbreviated acquisition schedule to allow additional time for nicotine pre-
treatment (i.e., 10 days). It is unclear whether these methodological differences 
affect the acquisition of oral methamphetamine self-administration; however, 
Shabani et al., 2013 suggest that increasing the number of operant trials per 
session facilitates the stabilization of behavior associated with each solution type. 
Taken together, findings from the present thesis and past research 
demonstrate that oral methamphetamine self-administration is attainable in both 
rats and mice. It is important to determine whether this effect in rats is age-
specific. Future research may consider testing oral methamphetamine self-
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administration in adult rats, as evidence suggests that drugs of abuse, such as 
methamphetamine, have a heightened reward value in adolescent rats, and this 
age group has a diminished sensitivity for the aversive effects of the drug 
(Schramm-Sapyta, Morris, & Kuhn, 2006; Schramm-Sapyta et al., 2009). 
The present data supports previous findings that nicotine exposure 
attenuates behavioral responding for methamphetamine during self-
administration and reinstatement (Hiranita et al., 2004; 2006; Neugebauer et al., 
2010). Specifically, adolescent male and female rats exposed to a low dose of 
nicotine (0.16 mg/kg) during the post-treatment (PD 35–~60) period had 
attenuated active nose pokes and reduced methamphetamine consumption 
across methamphetamine (40 mg/l) self-administration. Similarly, adolescent 
male and female rats exposed to a low dose of nicotine (0.16 mg/kg) during the 
pre-treatment (PD 25–34) period had attenuated total inactive nose pokes during 
the methamphetamine (40 mg/l) self-administration, extinction, and reinstatement 
phases. Neugebauer et al. (2010) found that adult male rats exposed to a higher 
dose of nicotine (0.40 mg/kg) showed a reduction in responding for 
methamphetamine access during self-administration, while a lower dose of 
nicotine (0.20 mg/kg) had no effect. This nicotine-induced attenuation of 
responding for methamphetamine was only observed at a higher fixed ratio 
schedule (i.e., FR 5) and was not observed at lower fixed ratio scheduling (i.e., 
FR 1) (Neugebauer et al., 2010). The authors attribute this finding to the 
susceptibility of nicotine to disrupt higher, but not lower rates of responding; 
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however, data from the present thesis suggests that a low dose of nicotine can 
also attenuate responding for methamphetamine at low rates of responding (i.e., 
FR 2). 
The present findings also show that nicotine exposure reduces responding 
for methamphetamine access during extinction and methamphetamine-primed 
reinstatement. Hiranita et al. (2004) found that adult male rats showed a 
reduction in methamphetamine seeking behavior during primed reinstatement 
following a repeated or single nicotine (0.30 mg/kg) exposure during a 
methamphetamine-withdrawal period. In addition, the nicotine-induced 
attenuation of methamphetamine seeking behavior was blocked by exposure to 
the nicotinic antagonist mecamylamine, thus demonstrating that the cholinergic 
system may be important in methamphetamine relapse (Hiranita et al., 2004; 
2006). Hiranita et al. (2006) found the attenuating effects of nicotine on 
methamphetamine seeking behavior was not altered by the muscarinic 
antagonist scopolamine, indicating that the inactivation of nicotinic ACh receptors 
is important for methamphetamine seeking behavior. 
Despite the clear methodological differences, the present findings and 
Hiranita et al. (2004; 2006) demonstrate a relationship between the nicotinic ACh 
system and methamphetamine seeking behavior. Within the CNS, the α4β2 and 
α7 nAChRs are the main receptor subtypes, with each receptor thought to play a 
different role in drug-seeking behavior (Grottick, Wyler, & Higgins, 2000). 
Compared to adults, adolescent α4β2 and α7 nAChRs expression and binding are 
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augmented in many different brain areas (Yuan et al., 2015). When exposed to 
the selective α4β2 nAChR antagonist DhβE in the nucleus accumbens core and 
prelimbic cortex, the AM251-induced (i.e., cannabinoid receptor 1 antagonist) 
attenuation of methamphetamine seeking behavior is blocked (Hiranita et al., 
2008). However, exposure to the selective α7 nAChR antagonist MLA does not 
alter the AM251-induced attenuation of methamphetamine seeking behavior, 
suggesting that normal functioning of the α4β2 nAChR plays an important role in 
methamphetamine seeking behavior (Hiranita et al., 2008). In addition, nicotine 
and ACh have a greater affinity for the α4β2 nAChR compared to α7, further 
indicating the importance of the α4β2 nAChR (Decker, Brioni, Bannon, & Arneric, 
1995; Gotti, Zoli, & Clementi, 2006). Taken together, it is possible that the 
nicotine-induced attenuation of methamphetamine seeking behavior observed in 
the present thesis may be due, in part, to the activation of the α4β2 nAChR. 
The present findings contrast with previous work showing that daily 
nicotine (0.16 mg/kg) treatment beginning in adolescence increases 
methamphetamine infusions, as well as active, inactive, and timeout lever 
presses in adult male rats (Pipkin et al., 2014). A potential explanation for the 
differing results is the self-administration procedures being used. Specifically, 
Pipkin et al. (2014) utilized intravenous self-administration of methamphetamine 
and found that nicotine exposure augmented responding for methamphetamine, 
whereas the present study used an oral method of methamphetamine self-
administration. The oral self-administration procedures used in the present study 
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were adopted from oral ethanol self-administration studies, wherein the drug is 
introduced in a sweetened solution and faded out across acquisition training 
(Ford et al., 2009). The drug is orally consumed and must first pass through the 
gastrointestinal lining and subsequently enters the blood stream. In contrast, the 
intravenous self-administration method requires surgery and the insertion of a 
catheter into the jugular vein, wherein the drug is directly infused into the 
bloodstream. Despite the disadvantages of oral self-administration procedures 
(e.g., delay in onset of the psychoactive effects of methamphetamine or the 
degradation of the drug via digestive enzymes and alternating pH levels), it is 
apparent that our rats did readily oral self-administer methamphetamine in the 
present thesis. It is not clear as to the extent this methodological difference 
played a role in the differing results found in the present thesis and Pipkin et al. 
(2014), but future direct comparisons of the two methamphetamine self-
administration procedures are warranted and may provide further clarity on this 
issue. 
Another explanation for the inconsistent results found in the present study 
and results from Pipkin et al. (2014) may be due to the age that rats were 
exposed to nicotine and tested on the methamphetamine self-administration 
procedures. Maturational changes in ACh and related neurotransmitter systems 
occur across early ontogeny and into adulthood (Yuan et al., 2015). For example, 
nAChR stimulation causes augmented ventral striatal DA release during 
adolescence when compared to adulthood (Azam et al., 2007). Nicotine 
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exposure leads to an increase of DA release via the mesolimbic reward pathway, 
in which consistently heightened DA levels results in the desensitization of these 
neurons (Pidoplichko, DeBiasi, Williams, & Dani, 1997). In addition, 
methamphetamine exposure leads to heightened DA release in the mesolimbic 
reward pathway (Dobbs & Mark, 2012). Age-related effects of nicotine exposure 
may be due, in part, to the protective mechanisms of nicotine against 
methamphetamine-induced dopaminergic deficits (Vieira-Brock et al., 2015). 
Stimulation of the α4β2 nAChR via nicotine exposure may act as a 
neuroprotective mechanism against methamphetamine-induced DA deficits 
(Baladi, Nielsen, McIntosh, Hanson, & Fleckenstein, 2016; Vieira-Brock et al., 
2015). Specifically, adolescent nicotine exposure (PD 41−61) attenuates 
methamphetamine-induced striatal dopaminergic deficits through α4β2 nAChR 
stimulation; however, this nicotine-induced neuroprotection was more 
pronounced in rats chronically treated with nicotine beginning in adolescence and 
ending in adulthood (Vieira-Brock et al., 2015). In contrast, nicotine exposure 
beginning in adulthood did not result in the same neuroprotection as adolescent 
nicotine administration, suggesting that the neuroprotective effects of nicotine 
against methamphetamine-induced DA deficits are age-related (Vieira-Brock et 
al., 2015). Taken together, these findings and data from the present thesis 
support the notion that nicotine exposure during the adolescent period acts to 
protect against methamphetamine-induced DA deficits and decreases the robust 
reinforcing properties of methamphetamine (Vieira-Brock et al., 2015). Moreover, 
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the nicotine-induced attenuation of responding for methamphetamine during self-
administration may be due to the age-related differences in the neuroprotective 
effects of α4β2 nAChR stimulation. Future research should consider investigating 
the specific neural mechanisms surrounding the nicotine-induced attenuation of 
responding for methamphetamine in adolescent rats. 
In the present thesis, female rats consistently responded for access to 
methamphetamine more than male rats during self-administration. Clinical 
reports show that females account for approximately 50% of adolescent 
methamphetamine users (Chen et al., 2014). Females report methamphetamine 
initiation at a younger age, a greater psychological burden and severity of 
methamphetamine use, and a more rapid increase in the frequency of 
methamphetamine use when compared to male users (Dluzen & Liu, 2008; Liu, 
Wang, Chu, & Chen, 2013; Rawson, Gonzales, Obert, McCann, & Brethen, 
2005; Simpson et al., 2016). Men show a significant correlation between 
methamphetamine cravings and depression or anxiety while females do not 
show the same correlation, thus indicating that females do not share some of the 
same side effects from methamphetamine use as men (Hartwell, Moallem, 
Courtney, Glasner-Edwards, & Ray, 2016). Similar to clinical reports, pre-clinical 
findings indicate that female rats acquire methamphetamine self-administration 
more rapidly and exhibit a more robust reinstatement than male rats (Kucerova, 
et al., 2009; Reichel et al., 2012; Roth & Carroll, 2004; Ruda-Kucerova et al., 
2015). Thus, the present data support and extend previous clinical and pre-
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clinical findings, in which female rats consistently respond more for access to 
methamphetamine than male rats during an oral self-administration procedure. 
In contrast to data from adolescent rats exposed to a low dose of nicotine 
(0.16 mg/kg), data from adolescent rats exposed to a high dose of nicotine (0.64 
mg/kg) suggests that nicotine exposure does not alter responding for access to 
methamphetamine during adolescence. The reason for this dose-dependent 
effect is unknown; however, higher doses of nicotine (e.g., > 0.60 mg/kg) can be 
averse (Torres et al., 2008). Given that a low dose of nicotine (0.16 mg/kg) in the 
present thesis altered responding for methamphetamine and a high dose of 
nicotine (0.64 mg/kg) did not, the aforementioned explanation is unlikely. 
Previous preclinical work is mixed in regard to the disruption of 
methamphetamine self-administration by a high dose of nicotine. Specifically, 
Neugebauer et al. (2010) found a reduction in responding for methamphetamine 
following exposure to a higher dose of nicotine (0.40 mg/kg), while a lower dose 
of nicotine (0.20 mg/kg) had no effect. Consistent with the present thesis, Pipkin 
et al. (2014) found that a high dose of nicotine (0.64 mg/kg) did not alter 
responding for methamphetamine. Pipkin et al. (2014) suggest these findings 
maybe due to response competition (i.e., high nicotine doses induce stereotyped 
behavior that interferes with responding for methamphetamine). Again, this 
explanation is also unlikely, as we found that a low dose of nicotine, but not a 
high dose, attenuated responding for methamphetamine. 
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Interestingly, we consistently found that inactive nose pokes were 
attenuated in rats treated with a low dose of nicotine (0.16 mg/kg) across 
methamphetamine self-administration, extinction, and reinstatement. This finding 
suggests that nicotine exposure reduced activity and impulsivity levels of rats 
during these periods. Prior clinical research suggests that impulsivity and drug 
dependence are positively correlated, with impulsivity being a strong predictor of 
nicotine and methamphetamine dependence (Balevich, Wein, & Flory, 2013; 
Ryan, MacKillop, & Carpenter, 2013; Tziortzis, Mahoney, Kalechstein, Newton, & 
De La Garza, 2011). Impulsivity also enhances an individual’s vulnerability to 
relapse (Kreek, Nielsen, Butelman, & LaForge, 2005). Therefore, the present 
study contrasts with previous clinical work and suggests that exposure to a low 
dose of nicotine (0.16 mg/kg) reduces impulsivity of rats during 
methamphetamine self-administration, extinction, and reinstatement. 
In addition, we found that female rats had heightened inactive nose pokes 
compared to male rats during methamphetamine self-administration and 
extinction. This finding suggests that female rats exposed to methamphetamine 
were more active and impulsive than similarly treated male rats. Previous clinical 
work suggests there are no sex differences in the impulsivity of 
methamphetamine users (Kogachi, Chang, Alicata, Cunningham, & Ernst, 2017). 
However, sex differences in methamphetamine users may be a function of age, 
as younger female methamphetamine users tend to have higher impulsivity 
scores (Kogachi et al., 2017; Semple, Zians, Grant, & Patterson, 2005). 
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Preclinical research suggests that sex differences in activity and impulsivity 
levels also occur in methamphetamine-treated rats. Consistent with the present 
study, female rats exposed to methamphetamine had more inactive lever 
presses than similarly-treated male rats (Reichel et al., 2012).  
The present results suggest that adolescents are exceedingly sensitive to 
nicotine doses. Adolescents who undergo treatment for methamphetamine 
addiction may benefit from the nueroprotective effects of exposure to a low dose 
of nicotine, while exposure to higher doses of nicotine may be counter 
productive. Thus, for adolescents who already present cigarette smoking 
behavior at the time of methamphetamine addiction treatment, total abstinence 
from both nicotine and methamphetamine may be a less effective form of 
treatment. It may be clinically beneficial to first treat the methamphetamine 
addiction, and subsequently treat the nicotine addiction. Regardless of the 
method of treatment for adolescent methamphetamine addiction, nicotine 
exposure should be closely monitored. 
Taken together, data resulting from exposure to a low dose of nicotine 
(0.16 mg/kg) and a high dose of nicotine (0.64 mg/kg) differentially supports the 
gateway theory of drug addiction, which suggests that using legal drugs, such as 
nicotine, increases the propensity for subsequent use of illicit drugs, such as 
methamphetamine (Lewinsohn et al., 1999). Within a strictly social context, it is 
likely that nicotine use may indeed lead to subsequent methamphetamine use, 
as approximately 97% of methamphetamine users also smoke cigarettes (Brecht 
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et al., 2004). From a purely pharmacological perspective, it is also apparent that 
moderate adolescent nicotine exposure can be protective against the robust 
reinforcing properties of methamphetamine; whereas, heightened adolescent 
nicotine exposure does not alter the reinforcing properties of methamphetamine.  
Conclusion 
The major findings from the present thesis are threefold: a) oral 
methamphetamine self-administration, extinction, and reinstatement are 
attainable in adolescent rats; b) exposure to a low dose of nicotine (0.16 mg/kg) 
attenuates the reinforcing properties of methamphetamine; c) exposure to a high 
dose of nicotine (0.64 mg/kg) does not alter the reinforcing properties of 
methamphetamine. The present research extends previous results showing: 1) 
oral methamphetamine self-administration is possible in mice (Shabani et al., 
2013); 2) exposure to nicotine has neuroprotective effects, resulting in the 
attenuation of methamphetamine seeking during methamphetamine self-
administration, extinction, and primed reinstatement (Baladi et al., 2016; Hiranita 
et al., 2004; 2006; Neugebauer et al., 2010; Vieira-Brock et al., 2015); and 3) 
exposure to a high dose of nicotine does not alter acquisition of 
methamphetamine self-administration (Pipkin et al., 2014). 
Future research may consider investigating oral methamphetamine self-
administration in adult rats, as adolescent rats exhibit heightened reward and 
diminished sensitivity to the aversive effects of drugs of abuse, such as 
methamphetamine (Schramm-Sapyta et al., 2006, 2009). Future research should 
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also consider investigating the specific neural mechanisms surrounding the 
nicotine-induced attenuation of responding for methamphetamine during self-
administration, extinction, and reinstatement in adolescent rats. 
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